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Abstract   
Diagnosis & dietary intervention in patients with diabetic 
gastroparesis 
 
Eva A Olausson 
 
Department of Internal Medicine and Clinical Nutrition, Sahlgrenska 
University Hospital, University of Gothenburg, Gothenburg, Sweden. 
 
Background: Gastroparesis is a diabetic complication, which is often under-recognised. Existing 
treatment options are limited and diagnostic methods not easily accessible. Aims of the thesis: To 
compare two alternative diagnostic methods for gastroparesis in patients with insulin-treated diabetes 
(DM) and to compare gastrointestinal (GI) symptoms and metabolic control after intake of diet with a large 
(LP) and small particle size (SP) in patients with insulin-treated DM with gastroparesis.  
Methods: In Paper I, gastric emptying of radiopaque markers (ROM) from the stomach using fluoroscopy 
was compared to gastric scintigraphy (current gold standard for diagnosing gastroparesis)) and the link to 
GI symptom severity was determined. In Paper II, the plasma glucose response after a test meal with a LP 
was compared to gastric scintigraphy in diabetic subjects with and without gastroparesis and the 
association with GI symptom severity was evaluated. In Papers III and IV, the effects of meals with a LP or 
SP were compared in randomised controlled trials (RCT). In Paper III, the effect of SP and LP diets on 
gastric emptying measured using scintigraphy and on the postprandial glucose response were studied in 
subjects with DM type 1 and gastroparesis and in healthy controls. In Paper IV, subjects with insulin-
treated DM and gastroparesis were treated with a SP or LP diet for 20 weeks and the effects on GI 
symptoms and metabolic control were compared between the groups.  
Results: Paper I: 115 patients with insulin-treated DM were included and 83 subjects had gastroparesis 
determined using scintigraphy. A moderately strong correlation was demonstrated between scintigraphic 
(% retained radioactivity at 120 min, T120) and ROM emptying (markers retained at 6 h) (r = 0.47; p 
<0.0001).The sensitivity and specificity of the ROM test was 34% and 97% respectively. Only scintigraphic 
gastric emptying correlated significantly with GI symptom severity with the strongest associations for 
fullness/early satiety (r = 0.34; p <0.001) and nausea/vomiting (r = 0.30; p <0.001). Paper II: We included 
83 patients with insulin-treated DM – 53 with gastroparesis and 30 with normal gastric emptying 
determined by gastric scintigraphy. The patients with gastroparesis had a blunted postprandial glucose 
response and demonstrated a lower maximum postprandial plasma glucose increase (p <0.05) and a 
lower incremental area under the plasma glucose curve (p <0.05). GI symptom severity had the best 
discriminative value to positively identify gastroparesis (sensitivity 87%, specificity 80%). By adding the 
plasma glucose response to GI symptom severity to identify patients with gastroparesis, the specificity 
increased (100%), but the sensitivity decreased (37%). Paper III: We studied seven patients with DM type 
1 and gastroparesis and seven healthy controls. The lag phase in the stomach and the T120 was 
significantly shorter and the postprandial blood glucose dip in diabetic subjects was less and of shorter 
duration after a SP meal compared to a LP meal. Gastric emptying did not differ significantly between 
groups after a SP meal. Paper IV: We randomised 56 subjects with insulin-treated DM and gastroparesis 
to eating diet with a SP ('intervention diet'), compared to the recommended diet for DM ('control diet') for 
20 weeks. A significantly greater reduction in the severity of the key gastroparetic symptoms – 
nausea/vomiting, postprandial fullness and bloating - were seen in patients on the intervention diet 
compared to the control diet. 
Conclusions: The alternative diagnostic methods for gastroparesis tested in this thesis – gastric emptying 
of ROM, plasma glucose response after a standardized test meal and GI symptoms assessment – can 
add information in the clinical setting, but cannot replace the current gold standard, gastric scintigraphy. A 
meal with a small particle size increases the gastric emptying rate and reduces the postprandial blood 
glucose dip in DM Type 1 subjects with gastroparesis. Dietary treatment with a SP significantly improves 
the key symptoms of gastroparesis in patients with DM.  
Key words: diabetic gastroparesis, gastrointestinal symptoms, scintigraphy, radiopaque markers, 
postprandial glucose, hypoglycaemia, gastric emptying, quality of life.  
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Introduction 
Over the past 25 years, my work has been focused on giving dietary advice 
to patients with diabetes mellitus (DM) at a specialized clinic at the 
Sahlgrenska University Hospital. The idea behind the research in this thesis 
stems from an incident some twenty years ago when I was privileged to 
participate in a one-day training programme for physicians on the subject of 
diabetic gastroparesis (i.e. delayed gastric emptying due to DM). One 
conclusion from the day was that the physicians had tried to help patients 
through dietary measures but always with the same disappointing results: 
“Dietary intervention for diabetic gastroparesis does not work”. This made 
me think: "Why does it not work – it must work." I had to try. I then recalled 
that, Inga Thorsdottir at the Department of Clinical Nutrition, a couple of 
years earlier had defended a thesis entitled: "Gastric emptying and 
postprandial glucose in healthy subjects and patients with diabetes mellitus 
type 2." In her thesis it was obvious that a diet with a small particle size 
(SP), such as mashed potatoes, passed through the stomach much more 
quickly than a diet with a large particle size (LP), such as pasta and rice, 
which ought to be valuable for patients with delayed gastric emptying. 
Based on this idea, I informed my patients with DM and gastroparesis- that 
the stomach needs to knead the diet into very small particles for it to pass 
through the pylorus as part of postprandial motility. I asked them to tell me 
what kind of food they thought suited them and told them about my dietary 
idea and asked them to try the SP diet in order to improve their symptoms.  
I specifically remember one patient with DM and severe neuropathy. The 
patient had been in hospital for two months because of nausea, bloating, 
diarrhoea and faecal incontinence. Now, after a few weeks at home, she 
was back in the hospital. She was instructed to eat a SP diet and she did 
not need to be hospitalised again for gastrointestinal (GI) symptoms. 
Another patient, who had a loss of appetite, nausea, abdominal fullness and 
bloating, as well as suicidal thoughts told me that it is acceptable to have 
poorer eyesight and to suffer from renal insufficiency but he could not 
handle being constantly nauseous. After eating diet with a SP, his appetite 
returned and he had no GI symptoms anymore. He looked forward to eating 
and no longer had suicidal thoughts. 
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I thereafter used these ideas about a SP diet to consecutive patients in my 
outpatient clinic and was heartened when I assessed the outcome in my 
first 65 patients who had clearly improved GI symptoms, fewer and milder 
episodes of postprandial hypoglycaemia and improved quality of life. I then 
realized that I had to perform proper studies to evaluate this diet in a 
scientifically sound way and the idea of starting a PhD project was born.  
 
Historical background 
The term 'gastroparesis' is a Greek word meaning 'a weakness of 
movement'. Gastroparesis is defined as delayed gastric emptying in the 
absence of an obstruction to outflow from the stomach and one of the most 
common causes is DM. The pathogenesis of this condition is still not 
understood very well although GI autonomic neuropathy is one plausible 
mechanism (1). Before the insulin era, diabetic gastroparesis was of little 
interest and the literature is devoid of any mention of that particular form of 
neuropathy. Gastric retention was first noted by Boas in 1925 (2). The 
radiological picture was described by Ferroir, who conducted the first 
thorough study of the stomach in diabetes subjects in Paris in 1937 (3). The 
focus was on hypochlorhydria, which was found in 60 per cent of 26 
patients undergoing gastric analyses. Using the then relatively new barium 
meal study, he described the following abnormalities: "X-ray examination 
showed that in diabetics, the stomach is generally very chronic but the 
motor responses are weaker than normal. Contractions are slow, lack 
vigour and die out very quickly in 59% of the diabetics. Not infrequently, 
pyloric incompetence may be found with a hypotonic pyloric sphincter 
producing rapid evacuation in most cases." The first detailed description of 
gastric retention secondary to diabetic visceral neuropathy was by Rundles 
in 1945 (4). The term 'gastroparesis diabeticorum' was coined by 
Kassander in 1958, when he also indicated that this syndrome could be 
present in relatively asymptomatic diabetic subjects (5). To date, 
gastroparesis is still often under-recognised, inadequately investigated and 
poorly managed (6, 7), despite the fact that the condition has been known 
for more than fifty years. 
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Background 
The incidence of DM is increasing worldwide. Population growth, ageing 
populations and urbanisation, with an associated lifestyle change, are likely 
to result in a 54% increase in worldwide numbers of people with DM 
between 2010 and 2030.                                         
It is estimated that worldwide DM prevalence will be 6.4% and 7.7% for in 
2010 and 2030 respectively (8). The total number among the adult 
population (aged 20-79 years) was about 285 million in 2010 and will be 
439 million in 2030. 
There is a difference between developed and developing countries. 
Between 2010 and 2030, there will be a 69% increase in the number of 
adults with DM in developing countries and a 20% increase in developed 
countries (8). The highest increase in prevalence will be in Africa with 98% 
in 2030 due to a growing population and increasing incidence. 
After several years of DM, the patient could develop, micro- and macro-
angiopathy complications. Retinopathy, nephropathy and neuropathy are 
micro-angiopathy complications and cardiovascular disease is a macro- 
angiopathy complication (9-13). These complications mean that the 
individual is suffering and is a financial burden on society as their care is 
expensive. The burden of DM complications is a growing problem.  
 
Development of diabetes care 
Knowledge of DM has increased and national and local diabetic care 
programmes have developed significantly over the past 20-30 years. 
Today, it is well known that good metabolic control, treatment of 
hypertension and hyperlipidaemia and absence of smoking are important in 
preventing complications (9, 10, 14-16). 
Severe complications can be prevented by, for example, using fundus 
photography, where fundus changes can be detected at an early stage. 
Laser treatment can prevent blindness and foot care can prevent different 
foot problems and amputations. 
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The development of a method to examine metabolic control over the past 8-
12 weeks, glycosylated haemoglobin (HbA1c), is a valuable tool for both 
patients and health care professionals (17, 18). Technical equipment that 
allows the patient to self-measure plasma glucose increases the options for 
achieving better metabolic control. Sophisticated technical equipment for 
continuous measuring of plasma glucose and insulin pumps with different 
technical solutions, e.g. different infusion rates at different times during the 
day, and delay of meal insulin doses, make it is easier to achieve good 
metabolic control. Other possible technical advantages with an insulin pump 
are that it can calculate the amount of insulin that is present in the body and 
how much insulin that is needed for a meal. All these developments 
increase the possibility of achieving good metabolic control, but despite this 
still many patients do not achieve good metabolic control and therefore 
develop complications. 
 
Gastrointestinal autonomy neuropathy – delayed gastric 
emptying 
Diabetic gastroparesis, i.e. delayed gastric emptying in the absence of an 
obstruction to outflow from the stomach, caused by gastrointestinal 
autonomic neuropathy (19) is another complication in DM (20, 21) and 
occurs in both DM type 1 (5, 22, 23) and DM type 2 (24, 25). The 
pathogenesis of this disabling condition is still not understood very well (21, 
26). A common view is that it is only patients with long disease duration that 
may have diabetic gastroparesis and that gastroparesis occurs only after at 
least 10 years of DM (25, 27, 28). However, in individual cases, 
gastroparesis may occur after just a few years of diabetes (29). Usually, the 
patient not only has the micro-complications and Gl autonomic neuropathy, 
but also other diabetic complications. Many patients with DM type 1 may 
have triopathy, i.e. neuropathy, retinopathy and nephropathy (28). Kockar et 
al. found a strong correlation between nephropathy, retinopathy and cardiac 
autonomic denervation and gastroparesis in subjects with DM type 1 and 2 
(30). Hyett et al. demonstrated a correlation between gastroparesis and 
cardiovascular disease, hypertension and retinopathy (31). For the patient, 
each of these complications is a burden and together they lead to a 
considerable reduction in quality of life and a conspicuous increase in 
mortality (32). Gastroparesis is sometimes associated with GI symptoms 
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and/or poor metabolic control (25), dehydration, electrolytes disturbances 
and/or nutritional deficiencies (33). 
 
Gastrointestinal symptoms 
Some patients with delayed gastric emptying have GI symptoms (31, 34-
37), while others are often asymptomatic, even with markedly delayed 
gastric emptying (5, 31, 38, 39). Conversely, Stanghellini et al. confirmed a 
high prevalence of delayed gastric emptying and gastroparesis in patients 
with upper GI symptoms (40). On the other hand, up to 50% of patients with 
markedly delayed gastric emptying had no GI symptoms whatsoever (39, 
41). In addition, in a population-based study, DM was associated with 
increased prevalence of upper and lower GI symptoms. This was linked to 
poor glycaemic control (42) but not to duration of DM or type of treatment 
(43). GI symptoms that occur in patients with gastroparesis are upper GI 
symptoms such as loss of appetite, meal-related cough, early satiety, 
nausea, vomiting, abdominal fullness, bloating and regurgitation, but also 
lower GI symptoms such as constipation, diarrhoea with gas, particularly 
nocturnal, and faecal incontinence, which cannot be attributed to the 
delayed gastric emptying per se, but to a generalized visceral neuropathy 
(44). However, these GI symptoms are not specific for diabetic autonomic 
neuropathy, but also occur in other conditions, such as irritable bowel 
syndrome, functional dyspepsia and a multitude of organic GI diseases. 
GI symptoms that correlate with gastroparesis are early satiety (25, 36), 
upper abdominal bloating/fullness (25, 34, 37), nausea/vomiting (25) and 
abdominal pain (45).However, it should be noted that the severity of GI 
symptoms does not always correlate with the rate of gastric emptying (34, 
38). 
Clinical manifestations are often underestimated and autonomic neuropathy 
should therefore be suspected in all diabetic patients with unexplained GI 
symptoms (7). Lack of GI symptoms does not exclude severe gastric 
emptying abnormalities (39). The lack of correlation between impaired 
gastric motility in the fasting state and dyspeptic symptoms shows that, on 
the basis of the clinical symptom analysis, the prevalence of such motor 
disorders could be underestimated (46). The early recognition of GI motility 
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alterations in autonomy neuropathy may be important for the better long-
term management of patients with DM (46, 47). 
 
Metabolic control 
Both symptomatic and asymptomatic diabetic gastroparesis seem to be 
associated with poor glycaemic control by causing a mismatch between the 
onset of action of the exogenous insulin or oral hypoglycaemic drug, gastric 
emptying and the absorption of nutrients from the small intestine (48). 
Decreased postprandial glycaemia and late increased glycaemia, resulted 
in higher glucose fluctuations in subjects with abnormal gastric emptying 
than in those with normal gastric emptying (49). Clinical incidence of 
severe, emergency hypoglycaemic events occur sometimes in diabetic 
gastroparesis (50). Hypoglycaemic activation of counter-regulation 
(Somogyi phenomenon) in all subjects with insulin-treated DM is best 
defined as hyperglycaemia following hypoglycaemia and is caused by 
insulin resistance induced by hypoglycaemic activation of counter-
regulation (51). This counter-regulation sometimes occurs for several hours, 
resulting in higher HbA1c (22, 39).  
In addition, acute changes in blood glucose concentration affect gastric 
motor function; gastric emptying is slowed down during hyperglycaemia (52, 
53) and is accelerated during hypoglycaemia (54). Hyperglycaemia should 
be taken into account in the treatment of the patient, as gastric emptying is 
slower than necessary. At a glucose level of 8 mmol/L, gastric emptying is 
already slower than at 4 mmol/L (53). It is therefore logical that DM patients 
have more severe postprandial fullness during hyperglycaemia than during 
euglycaemia (55).  
 
Nutritional status 
In patients with gastroparesis, the presence of GI symptoms is associated 
with eating problems, potentially resulting in food aversion. Patients with 
gastroparesis are thus at risk of weight loss and malnutrition. 
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In 2011, Parkman et al. published the first large study aimed at determining 
nutritional deficiencies in diabetic and idiopathic gastroparesis. In total, 194 
patients (64%) reported caloric-deficient diets, defined as <60% of 
estimated daily total energy requirements. More severe symptoms (bloating 
and constipation) were characteristic of patients who reported an energy-
deficient diet, and 82% of the subjects had protein intake <0.6 g/kg body 
weight.  Some patients have protracted nausea, vomiting and diarrhoea, 
making it difficult to maintain hydration and electrolyte balance.  
Deficiencies in the intake of vitamins and minerals from diet ranged from 
30% to 86% of patients (56). However, nutritional consultation took place 
infrequently (56). 
The current dietary therapy for patients with diabetic gastroparesis is based 
on a few studies that changed one parameter at a time in normal volunteers 
and measured the effects on gastric emptying. Although the results from 
some of these interventions have reached statistical significance, they have 
not been shown to be clinically significant (57). Theoretically, a host of 
factors can slow gastric emptying but no clinical trials have been conducted 
in patients with gastroparesis to determine the success of any dietary 
interventions (57). 
No randomised dietary study has been performed in patients with 
gastroparesis (58). For patients who fail to stabilise their weight loss or who 
cannot gain weight with oral feeding, enteral nutrition support may be 
indicated. Enteral nutrition not only allows the patient to stay hydrated and 
nourished but also provides ready access for consistent medication delivery 
(57).  Occasionally, a jejunostomy may be helpful to maintain nutrition (59). 
Parenteral nutrition (PN) is associated with more infectious complications 
and is significantly more expensive (59). However, many patients with 
gastroparesis are drug refractory and invariably do not do well with enteral 
or parenteral access. Historically, these patients have been without 
effective therapeutic options. The development of gastric electrical 
stimulation has allowed patients with severe drug-refractory gastroparesis 
to be treated successfully and it may also improve survival rates (60). To 
summarize, nutritional but also psychological support is important for these 
patients, but unfortunately often neglected (61).  
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Physical and psychological well-being 
Several studies have addressed the prevalence of GI symptoms in DM and 
their importance for physical and psychological well-being. GI symptoms in 
unselected DM subjects impact negatively on health-related quality of life in 
DM and this is similar in community and outpatient DM subjects. Increased 
levels of state anxiety, depression and neuroticism are associated with 
upper and lower GI symptoms in DM (62). 
Parkman et al. arrived at the conclusion that quality of life in gastroparesis 
subjects, as assessed by SF 36, was below that of the US population. 
Gastroparetic subjects with DM type 1 had the lowest mental health 
summary score and in diabetes type 2 the lowest physical health summary 
scores were seen (63). Also the fact that GI symptoms in subjects with 
gastroparesis decrease quality of life has been confirmed in several studies 
(64, 65). Not surprisingly, nausea, vomiting (66) and bloating symptoms 
correlate with poorer quality of life in patients with DM and gastroparesis 
(67). 
Also depressive symptoms have been demonstrated in diabetic 
gastroparesis, and by using the Beck Depression Index, 25% of the patients 
in the diabetic gastroparesis type 1 group were found to have severe 
depression and 17% of the patients in the diabetic gastroparesis type 2 
group. Moreover, with the State-Trait Anxiety Inventory questionnaire, state 
and trait anxiety scores were found to be severe in a large proportion of 
these patients – around 45% and 30% in types 1 and 2 respectively (63).  
To summarize, gastroparesis can be extremely troublesome, causing poor 
metabolic control and GI symptoms and result in poor quality of life (33, 68). 
 
Care-intensive patients 
Around 20% of hospitalised DM type 2 patients had delayed gastric 
emptying (36). A study in the USA found that gastroparesis-related 
hospitalisations from 1995-2004 had risen. Admission with gastroparesis as 
the primary diagnosis increased by 158% and 138% in those with the 
condition as a secondary diagnosis (69). The potential explanations for this 
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rise include the wider recognition of the disease, higher prevalence of DM 
and longer survival of DM patients (70).  
Jung et al. (28) provided conclusive evidence that gastroparesis was 
associated with higher mortality but also with morbidity (31), increased 
hospitalisation and emergency department and doctor visits by DM types 1 
and 2 patients with classic symptoms of gastroparesis. Patients with a 
documented delay in gastric emptying were more likely to have 
cardiovascular disease, hypertension and retinopathy, suggesting that the 
underlying complication might be related to micro-angiopathies or macro-
angiopathies, which are known complications of poor metabolic control (28). 
In a recent study, the healthcare consumption and the GI symptom severity 
in a small group of patients with gastroparesis and GI symptoms was 
determined, and it was confirmed that these patients form a high-risk group 
in terms of cost, quality of life, morbidity and mortality (71). 
 
Normal gastric emptying 
The stomach is composed of several regions with different yet 
complementary actions. The fundus is a storage area for food and the 
antrum and pylorus ensure grinding and move the stomach contents from 
the fundus to the antrum. The stomach is an innervated muscle and the 
motor function is co-ordinated with that of the pylorus to ensure 
fragmentation of the food bolus and ensure digestion regularity (50). 
Peristaltic activity is dependent on the pacemaker in the stomach, located 
on the greater curvature (Interstitial cells of Cajal). Peristaltic activity 
propagates down to the antrum and pylorus at a frequency controlled by a 
natural rhythm related to the gastric slow waves, and occurs at a maximum 
frequency of about three cycles per minute (50). The slow waves arrive 
continuously while the peristaltic contractions occur only after food intake. 
Solid nutrients usually empty in two phases over 3-4 hours. An initial lag 
phase (i.e. the retention phase) is followed by a propellant phase of 
relatively constant emptying. During the first phase, diet is churned while 
antral contractions propel particles towards the closed pylorus. Diet is 
emptied once it has been broken down into particles approximately 2 mm in 
diameter (72). Liquid diet is usually emptied faster, especially with large 
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volumes. If there is an increased number of calories in the liquid, emptying 
is relatively constant over time (72). 
In the fasting state, gastric motility undergoes a cyclical pattern, termed the 
'migrating motor complex' (MMC). This consists of phase I (motor 
quiescence, ~40 min), phase II (irregular contractions, ~50 min) and phase 
III (regular contractions of three per minute for ~5–10 min). Large, 
indigestible solid particles are usually emptied from the stomach into the 
small intestine during phase III (73).  
 
Pathophysiology of diabetic gastroparesis 
Gastroduodenal motor abnormalities in DM patients with delayed gastric 
emptying include parasympathetic nerve damage. However, changes in the 
secretion of hormones, such as motilin and ghrelin, are also involved in the 
pathophysiological process. These abnormalities lead to excessive 
relaxation in the corpus, less frequent antral contractions, antroduodenal 
incoordination (74, 75) and pyloric spasm (75). It should be noted that the 
latter rarely occurs in isolation and is typically associated with antral 
hypomotility (75). Abnormalities in small bowel motility might result in 
delayed gastric emptying of solids. Gastric motor dysfunction might be 
associated with small bowel dysmotility caused by a common mechanism 
(74). In addition, disturbances of proximal gastric compliance, either 
increased (76) or decreased (77), have been reported and could also 
contribute to symptoms. 
In a fasting condition, the chronic influence of diabetic neuropathy on the 
stomach is decreased amplitude of the pressure waves in the antrum during 
MMC phase III, significantly fewer contractions and in half of the diabetic 
gastroparesis subjects a total loss of MMC phase III in the stomach (78).  
 
Diagnosis 
Gastroparesis is most often idiopathic, diabetic or postsurgical in nature, 
with other causes representing a minority of cases (79). Diabetic 
gastroparesis is found in about one-third of all gastroparesis patients (80). 
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Kassander coined the term 'gastroparesis diabeticorum' in asymptomatic 
patients with DM type 1 (5). However, other definitions were formulated 
later. Gastroparesis, literally defined as 'weakness' of the stomach, is 
characterised by an abnormal delay in gastric emptying in the absence of 
mechanical obstruction (81). There is a lack of a standard definition for 
gastroparesis, although it is frequently defined as a rate of emptying that is 
at least two standard deviations above the normal mean, usually 
determined using a scintigraphic technique (82). It has been suggested that 
a distinction should be made between gastroparesis and delayed gastric 
emptying. It has been suggested that gastroparesis, or gastropathy, be 
defined based on the presence of upper GI symptoms alone when other 
causes, including gastric outlet obstruction, have been excluded (83, 84). 
However, there is a lack of consensus as to its appropriateness. While 
many patients with gastroparesis have upper GI symptoms, there is a 
relatively poor relationship between symptoms and the rate of gastric 
emptying (82, 85). Gastroparesis can also have other important clinical 
manifestations, such as impaired glycaemic control in insulin-treated DM 
patients (85). It should be recognised that in many cases the delay in 
gastric emptying of solids or liquids is relatively modest and it can be 
argued that a distinction should be made between gastroparesis and 
delayed gastric emptying, i.e. that a diagnosis of gastroparesis should be 
restricted to those patients in whom emptying is grossly delayed (83). 
 
Incidence 
Few studies have addressed the incidence of gastroparesis. The 
cumulative proportions of patients who developed gastroparesis over a 10-
year period were 5.2% for type 1 DM, 1.0% for type 2 DM, and 0.2% for 
non-diabetic controls (70). The age-adjusted incidence of definite 
gastroparesis per 100,000 person years for the period 1996-2006 was 2.4 
(95% confidence interval, CI, 1.2-3.8) for men and 9.8 (95% CI, 7.5–12.1) 
for women (28). When comparing DM type 1 and type 2, patients with DM 
type 2 are 13 years older at onset of symptoms associated with 
gastroparesis than patients with DM type 1 (63). 
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Prevalence 
The prevalence of gastroparesis in the community is difficult to estimate 
due to the relatively poor correlation of symptoms with gastric emptying rate 
and the need to apply a diagnostic test in a community setting. It is unclear 
whether the majority of patients with gastroparesis seek healthcare or how 
often they are referred to gastroenterologists. The true prevalence of 
gastroparesis is therefore unknown. In the DM population, the prevalence of 
gastroparesis is also difficult to estimate due to the apparently higher 
prevalence of the disorder in university centres than in smaller hospitals, in 
a primary care setting and in the community. A widely available diagnostic 
test that could be applied in a standard fashion is currently lacking in the 
primary care setting (86, 87).  
Gastric scintigraphy is considered the gold standard worldwide. This 
method is expensive and requires specialised staff. One problem is that 
scintigraphy is not always performed according to the same standards. In 
gastric scintigraphy, measurement takes place either during two- or four 
hours and different test meals are used, hence consensus 
recommendations are not always followed (86, 88). In most centres 
different reference values are used for men and women (86), as women 
have slower gastric emptying than men. However, there are also 
differences between pre- and post-menopausal women depending on 
hormones (89). Moreover, in diabetic gastroparesis it is important to assess 
gastric emptying in a euglycaemic condition as hyperglycaemia delays 
gastric emptying (52, 53, 90). The study design is also important. Are the 
samples selected or unselected and which inclusion criteria are applied?  
Most population-based DM studies in subsets of patients at risk of 
developing gastroparesis have focused on symptoms rather than gastric 
scintigraphy findings (81). In such investigations, 10–18% of individuals with 
DM report symptoms consistent with upper GI dysmotility, such as nausea 
and vomiting (43, 91, 92). Jung et al. made an attempt to study the 
prevalence of all kinds of gastroparesis in the general population. After 
studying the complete medical records in Olmsted County, Minnesota from 
1996 to 2006, there were 3,604 potential cases of gastroparesis. After 
exclusion criteria were applied, 432 subjects remained. The inclusion 
criteria were: Definite, probable and possible gastroparesis and gastric 
emptying investigated using scintigraphy. The age-adjusted (compared to 
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the white population in the US in 2000) prevalence of definite gastroparesis 
per 100,000 persons was 24.2 (95% confidence interval [CI], 15.7– 32.6) for 
both genders, 9.6 (95% CI, 1.8 –17.4) for men and 37.8 (95% CI, 23.3–
52.4) for women (28).  
In another study, the prevalence of gastroparesis was 36% in symptomatic 
subjects with DM type 1 and 2 (93). Other studies have also confirmed that 
the prevalence in females is higher than in males (36, 70).  
A study in the DM population assessed gastric emptying of a solid meal 
with scintigraphy under euglycaemic conditions (23), confirming the 
prevalence of gastroparesis in unselected patients with DM type 1 at 34%. 
In another study, the prevalence was 28% in DM type 1 (35). In two studies 
investigating selected groups of patients with long-standing type 1 DM, the 
prevalence was 40-44% (22, 48). 
The prevalence of gastroparesis in subjects with DM type 2 is in the range 
30-58% (94-96). However, these studies are limited by the small sample 
sizes, the presence of hyperglycaemia during testing and the variety of test 
meals and diagnostic methods used. In the study performed by Annese et 
al., 34% of patients had peripheral and autonomic neuropathy and 36% of 
the patients showed abnormal esophageal and gastric motor function (96).  
 
Diagnostic methods 
There are various means of assessing gastric emptying (97). The current 
gold standard is gastric scintigraphy, but other techniques have been 
evaluated and/or are under evaluation. Some of these will be reviewed 
below. 
Scintigraphy. Using scintigraphy, the emptying time and intragastric 
distribution of solid and/or liquid meal components can be evaluated. 
Scintigraphy, which is non-invasive and reproducible, remains the most 
sensitive and accurate method and is considered to be the 'gold standard' 
technique. It measures the intragastric distribution and emptying of a solid 
or liquid meal labelled with Technetium- 99m,99mTc. The isotope binds to 
meal protein and a gamma camera registers the 99mTc passage through the 
stomach. Gastric emptying is monitored for 3-4 hours after meal 
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consumption. The gastric emptying is evaluated as follows: Lag phase = the 
time from finished meal before the gastric emptying begins, T50 = at that 
time, 50% of the isotope has passed through the stomach and R120 or T120 = 
the remaining isotope percentage in the stomach 120 minutes after the 
ingested meal. This method is expensive and requires specialised staff 
(86), and is not easy accessible for many clinicians. Moreover, radiation 
exposure is another drawback with this technique. Alternative methods are 
therefore needed.  
Breath tests. These tests assess gastric emptying using meals labelled 
with stable isotopes, such as 13C-acetate or 13C-octanoate and, in contrast 
to scintigraphy, does not involve exposure to ionising radiation. It has good 
reproducibility and the results have been reported to correlate well with 
scintigraphy, with a sensitivity and specificity of 86-89% and 80% 
respectively for the presence of delayed gastric emptying, including a DM 
population (98, 99). Furthermore, they are easy to administer and are 
inexpensive (100, 101). After ingestion, the labelled meal passes through 
the stomach to the small intestine, where the 13C-acetate or 13C-octanoate 
is absorbed, metabolised into 13CO2 in the liver and exhaled via the breath. 
13CO2 in breath samples is analysed by means of mass spectrometry (45, 
101). Although this technique has advantages over scintigraphy, 
information relating to the validity of breath tests in patients with markedly 
delayed gastric emptying is limited. 
Ultrasonography. Two-dimensional ultrasonography is a convenient, valid, 
non-invasive method of measuring the emptying of liquids or semi-solids as 
well as antral contractions and transpyloric flow (102, 103). The more 
recently applied three-dimensional ultrasonography can provide 
comprehensive imaging of the stomach, including information about 
intragastric meal distribution, and has been validated against scintigraphy to 
measure gastric emptying in both healthy subjects and in patients with 
diabetic gastroparesis (104). Although ultrasonography is readily available 
and does not involve exposure to radiation, obesity, abdominal gas and the 
need for an experienced operator limit its widespread use. 
SmartPill®. Swallowed capsule telemetry (SmartPill®) uses an ingestible 
capsule that measures intraluminal pH to determine the gastric emptying 
rate. Moreover, the capsule can also record pressure during the passage 
through the GI tract as a measure of contractions, as well as temperature. 
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This method has been reported to correlate well with scintigraphy with good 
sensitivity (82%) and specificity (83%) to diagnose delayed gastric 
emptying(61) but has only recently been approved for use in Europe. 
Emptying of the capsule presumably occurs after that of digestible meal 
components, and this technique has been criticised for measuring re-
appearance of gastric fasting motility (MMC, phase III) rather than emptying 
of a meal. 
The paracetamol (acetaminophen) absorption test. Another principle 
used to measure gastric emptying is the absorption of paracetamol 
assessed with serial blood samples after intake of paracetamol. The 
paracetamol (acetaminophen) absorption test is a simple bedside test, but 
its usefulness is limited to evaluation of the emptying of liquids and is 
generally not recommended as a diagnostic tool as its accuracy is 
moderate at best (105). 
Radiopaque markers. Emptying of radiopaque markers (ROM) 
(indigestible solids) from the stomach using fluoroscopy is an easy and 
inexpensive method and is available at all hospitals. There is a significant 
correlation between gastric emptying of ROM  with gastric scintigraphy in 
healthy subjects and in a small group of subjects with insulin-dependent DM 
(106). However, the correlation between gastric emptying of ROM and 
gastric scintigraphic emptying in larger groups of patients with gastroparesis 
has not been studied. 
Magnetic resonance imaging. Magnetic resonance imaging has also been 
used to measure gastric emptying and wall motions of the stomach. 
Abdominal scans are generally obtained in the supine position every 15 min 
before and after a predominantly liquid meal. This method is still not widely 
spread and is under development. An advantage with this method is that it 
does not expose the subject to radiation, but it is limited by the use of 
specialized equipment, by being expensive and by using the supine 
position.    
 
Limitations with existing diagnostic methods 
Several of the existing diagnostic methods have limitations, such as 
radiation exposure, expenses etc., which has been described above. One 
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of the major limitations is availability, and there is a limited number of 
methods for investigating gastroparesis at small hospitals, which may be 
one reason why this condition has been investigated inadequately. In order 
to improve the diagnostic management of gastroparesis access to different 
diagnostic methods should be available in all hospitals. Fluoroscopy is 
available at all hospitals, and therefore we aimed to study the correlation 
between gastric scintigraphy and the ROM method in patients with 
gastroparesis, to evaluate if this widely available method could be used 
more in the diagnostic approach in patients with suspected delayed gastric 
emptying. Moreover, as patients with DM and delayed gastric emptying 
have an altered glucose response after meal intake (39, 107, 108) and 
some of them also report upper GI symptoms (25, 34, 36), we also 
hypothesized that measuring blood glucose after meal intake and to assess 
the symptom profile could be helpful in finding DM patients with suspected 
gastroparesis. Our research question was therefore if GI symptoms in 
recent weeks and/or glucose response after a test meal could be a 
screening method to strengthen the suspicion of gastroparesis? 
 
Treatment options for patients with diabetic gastroparesis 
The treatment for patients with diabetic gastroparesis is aimed at reducing 
GI symptoms, optimising glucose control and correcting fluid, electrolyte 
and nutritional deficiencies (109). The principles in the management of 
patients with diabetic gastroparesis is based on dietary/nutritional 
adjustments, optimisation of the glycaemic control, pharmacologic therapy 
with prokinetics or antiemetics, avoidance of opioids, and in very select 
cases specialized therapies such as surgery, botox injections or gastric 
electrical stimulation (110).   
Dietary/nutritional treatment. To date, the recommendation for 
management of gastroparesis using dietary/nutritional measures is as 
follows: 
1. The first line of management for gastroparesis patients should include 
restoration of fluids and electrolytes, nutritional support and, in DM patients, 
optimisation of glycaemic control. (Strong recommendation, moderate level 
of evidence.) 
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2. Oral intake is preferable for nutrition and hydration. Patients should 
receive counselling from a dietician regarding the consumption of frequent, 
small-volume nutrient meals that are low in fat and soluble fibre. If they are 
unable to tolerate solid food, then the use of homogenised or liquid nutrient 
meals is recommended. (Conditional recommendation, low level of 
evidence.) 
3. Oral intake is the preferred route for nutrition and hydration. If oral intake 
is insufficient, then enteral alimentation by jejunostomy tube feeding should 
be pursued (after testing nasoenteric tube feeding). Indications for enteral 
nutrition include unintentional loss of 10% or more of the usual body weight 
during a period of 3-6 months and/or repeated hospitalisation for refractory 
symptoms. (Strong recommendation, moderate level of evidence.) 
4. For enteral alimentation, postpyloric feeding is preferable to gastric 
feeding, as gastric delivery can be associated with erratic nutritional 
support. (Conditional recommendation, low level of evidence.) 
5. Enteral feeding is preferable to parenteral nutrition. (Conditional 
recommendation, low level of evidence.) (109). 
However, so far there is no randomised, controlled diet trial for 
gastroparesis. Dietary advice comprises suggestions that stem from the 
results of studies performed in subjects with normal gastric emptying. The 
major features in the dietary recommendations are to decrease fat (111-
113) and fibre (114), as these slow gastric emptying. However, most 
studies added soluble fibre to liquid meals, which may have more impact of 
gastric emptying than soluble fibre added to a solid meal. In healthy 
subjects, a fat liquid test meal increased the lag period and decreased the 
slope of the emptying curve. During the lag period, there was initial filling of 
the distal stomach, followed by redistribution of the distal stomach contents 
back into the proximal stomach. At the onset of total gastric emptying, the 
proximal stomach also emptied (111). This redistribution must be taken 
account in patients with delayed gastric emptying.  
In order to prevent formation of bezoars in the stomach of patients with 
delayed gastric emptying, advise to avoid foods that may lead to 
phytobezoar formation, such as oranges, persimmons, coconuts, berries, 
green beans, figs, apples, sauerkraut and Brussels sprouts, should be 
given (115). Moreover, small, frequent meals are suggested as large meals 
slow down gastric emptying in healthy subjects (116), and the lag phase 
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was prolonged in both solid and liquid large meals compared with smaller 
meals (117).  
Pharmacologic therapy. The aim of the therapy is to improve the 
efficiency of the gastric pump and to relieve GI symptoms. Two classes are 
available to treat affected patients – prokinetic and antiemetic drugs. Of 
these, only prokinetics have been specifically studied in gastroparesis, 
whereas antiemetics, such as phenotiazines, antihistamine agents and 
serotonin 5HT3 receptor antagonists are used empirically based on their 
effect on nausea and vomiting. Only prokinetics will be described in some 
detail here.  Prokinetics are the most commonly used medications for 
gastroparesis. These stimulate peristalsis and could specifically improve 
gastric pump function by influencing antral contractility and rhythm as well 
as antroduodenal co-ordination. Established prokinetic agents, including 
metoclopramide, domperidone and erythromycin, form the mainstay of the 
treatment. Metoclopramide has both prokinetic and antiemetic properties. 
The long-term efficacy of metoclopramide, a dopamine D2 receptor 
antagonist, has not been established clearly and the prokinetic effects may 
potentially diminish over time (118). Metoclopramide is available in several 
formulations. It can be given orally, intravenously and subcutaneously. The 
use of metoclopramide is marked by a high prevalence of adverse effects 
on the central nervous system. Mild central neurological effects, including 
restlessness, agitation, dizziness and drowsiness, occur in up to 40% of 
patients, while dystonic reactions occur in approximately 1% (118). During 
more prolonged use, tardive dyskinesia may develop, which is potentially 
irreversible and may occur in 1-10% of patients who have been taking the 
drug for more than three months (119). These side effects greatly 
diminishes the clinical usefulness of metoclopramide. 
Domperidone, another dopamine antagonist, appears to be effective in the 
management of symptomatic gastroparesis, including that associated with 
DM (120), with fewer side effects than metoclopramide (121). It is relatively 
impermeable to the blood-brain barrier and therefore causes fewer adverse 
central neurological effects (122). Acute administration of domperidone has 
been reported to accelerate gastric emptying of solids and liquids in both 
healthy subjects and in DM patients with autonomic neuropathy. The 
greatest effect is observed in patients with a marked delay in gastric 
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emptying (123). Domperidone has also been shown to improve quality of 
life in patients with DM through its alleviation of GI symptoms (120).  
Erythromycin is a macrolide antibiotic that also has the ability to act as a 
motilin agonist through its interaction with motilin receptors. Erythromycin 
accelerates gastric emptying by increasing the frequency and amplitude of 
antral and duodenal contractions in the proximal stomach (85). The effect of 
erythromycin on GI symptoms is controversial, although there is evidence to 
suggest that it improves bloating in patients with functional dyspepsia and 
gastroparesis (82). However, long-term use of erythromycin for 
gastroparesis is less well substantiated and tachyphylaxis is thought to 
develop due to down-regulation of motilin receptors with chronic use. 
Furthermore, there is the potential risk of bacterial resistance (124). The 
major adverse effects of erythromycin are well recognised and include 
abdominal pain and cramping, nausea, diarrhoea, vomiting and skin rash. 
Erythromycin may also cause adverse cardiac effects (124).  
 
Surgery and gastric electric stimulation 
Some subjects with gastroparesis remain unsatisfactory despite 
dietary/nutritional adjustments, optimisation of the glycaemic control, and 
the use of prokinetic and/or antiemetic drugs. In these cases, gastric 
electrical stimulation is an option. Also surgical procedures, such as venting 
gastrostomy, gastrectomy or pyloroplasty, may be used in very select cases 
(110). Gastric electrical stimulation delivers high frequency, low energy 
electrical stimulation to the stomach and through an unknown mechanism 
many patients with diabetic gastroparesis demonstrate a substantial 
reduction of the key gastroparetic symptoms, especially nausea and 
vomiting (21). In the first multi-centre trial, thirty-eight highly symptomatic 
patients with drug-refractory gastroparesis with differing aetiology, including 
diabetic gastroparesis, received gastric electrical stimulation. In 97% of 
these patients more than 80% reduction in vomiting and nausea (including 
diabetic gastroparesis) was reported. (125). Several studies have followed 
and confirmed these initial positive results, especially in diabetic 
gastroparesis (21). However, access to a gastric pacing is limited to a few 
hospitals and few patients are in a position to benefit from this method. The 
cost is also rather high, limiting a widespread use of this treatment option. 
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General and specific aims of this thesis 
Based on gaps in the existing literature and building on previous clinical and 
scientific  experience with these patients our aims with the studies included 
in this thesis were:   
1. To compare two alternative diagnostic methods for gastroparesis 
using gastric scintigraphy, the current golden standard, in patients 
with insulin-treated DM.  
2. To compare GI symptoms and metabolic control after intake of diet 
with a LP and SP in patients with insulin-treated DM with 
gastroparesis. 
 
Paper I 
To evaluate the correlation between emptying of ROM from the stomach 
using fluoroscopy and gastric scintigraphy in a large group of patients with 
insulin-treated DM in order to define a potential role for ROM emptying in 
the management of patients with DM and clinical suspicion of delayed 
gastric emptying. We also wanted to assess the link between different GI 
symptoms, ROM emptying and scintigraphic gastric emptying of solids. 
 
Paper II 
To characterise thoroughly the postprandial glucose response after a test 
meal with LP in patients with DM and clinical suspicion of gastroparesis and 
to assess whether this, together with a questionnaire-based assessment of 
the severity of GI symptoms during the preceding two weeks, could help to 
predict delayed gastric emptying determined with gastric scintigraphy.  
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Paper III 
To evaluate the effect of meal particle size on gastric emptying and 
postprandial blood glucose variations after a meal. To achieve this, we 
measured the gastric emptying time and postprandial blood glucose 
response in patients with DM Type 1 and gastroparesis and in healthy 
controls by comparing meal with a LP with the same meal with a SP. 
 
Paper IV 
To compare the effects of a dietary intervention that recommends diet with 
SP with the standard dietary recommendations given to patients with DM, in 
insulin-treated DM subjects with gastroparesis. Our primary aim was to 
improve GI symptoms associated with gastroparesis and the secondary 
aims were to assess the effects on body weight, nutritional intake, 
metabolic control, mental health and quality of life.  
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Methodological considerations 
Subjects 
The thesis summarises four studies incorporating insulin-treated DM 
subjects with and without gastroparesis and healthy control subjects; 
Papers I and II deal with validation of diagnostic and screening methods for 
gastroparesis. Papers III and IV deal with randomised trials studying the 
relationship between LP and SP in the diet and gastric emptying, 
postprandial plasma glucose and GI symptoms in subjects with insulin 
treated DM and gastroparesis. 
The subjects included in Papers I, II and IV in this thesis were insulin 
treated DM patients recruited from DM outpatient clinics in eleven hospitals 
and four primary care teams in Region Västra Götaland of Sweden. The 
teams were informed about the study through personal visits to the clinics 
by EO and through e-mails. During the visits, the teams were informed 
about signs and symptoms associated with gastroparesis in order to find 
patients who had still not received a diagnosis. The recruitment process 
began in August 2007 and was completed in November 2011. 
Paper I. 115 subjects with insulin treated DM and with a wide range of GI 
symptom severe were included. 
Paper II. Insulin-treated DM patients with and without suspected 
gastroparesis were included. 
Paper IV. Insulin treated DM patients with suspected gastroparesis were 
included. Only 14 DM subjects had normal gastric emptying and 2 subjects 
with gastroparesis were unwilling to participate in the study. Figure 1. 
Paper III. These patients with gastroparesis were recuited from the 
Diabetes outpatient clinics, Sahlgrenska University Hospital and Kungälv 
Hospital in September 1996 and March 1998. The gender, age and body 
mass index matched healthy controls were recruited via an newspaper 
advertisement. 
Exclusion criteria for all the studies were as follows: previous 
gastrointestinal surgery except appendectomy, severe psychiatric disease, 
32 
 
sequelae after cerebrovascular disease, untreated disease with a potential 
impact on gastric emptying, or GI symptoms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Study subjects in Papers I, II and IV.                                                                         
GP = Subjects with gastroparesis. NGE = Subjects with normal gastric 
emptying.                                                                                                  
*The subjects excluded after Paper I and could not participate in Paper II 
due to high plasma glucose at the start of the test.                                                                                                     
** Subjects excluded before Paper IV: subjects with normal gastric 
emptying were not asked to participate in Study II. The two subjects with                                                                                          
gastroparesis did not want to participate in Paper IV.                                                                                                                    
 
 
 
Patients from Region 
Västra Götaland, Sweden 
115 
subjects 
Paper I                      
83 GP 32 NGE 
 
Paper ll                                          
53 GP                              
30 NGE 
 
12 GP                  
11 NGE 
Paper IV                               
56 GP 
39 GP  
2 GP 19 NGP  
13 GP *                 
7 NGE 
53 subjects 
unwilling to 
participate 
2 GP 14 NGE** 
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Approval by the Radiation Safety Committee and Ethical 
Review Board                      
The studies were approved by the Radiation Safety Committee at 
Sahlgrenska University Hospital, Sahlgrenska Academy, University of 
Gothenburg, and the Regional Ethical Review Board in Gothenburg, 
Sweden. Each participant received verbal and written information about the 
study and gave their written, informed consent before any study related 
procedure was performed. 
 
Study design 
Papers I and II. Before the test, the patients had completed the 'Patient 
Assessment of Gastrointestinal Disorders Symptom Severity Index (PAGI-
SYM)' and Gastroparesis Cardinal Symptom Index (GCSI). The subjects 
arrived at the hospital at 8 am in a fasting condition (10 hours). Alcoholic 
beverages were not permitted 24 hours before the test and drugs with an 
effect on GI motility were not permitted for 48 hours before the test. 
Smoking was not permitted during the test. The plasma glucose had to be ≤ 
10.0 mmol/L at the beginning of the meal and the subjects had taken their 
ordinary dose of insulin for breakfast, adjusted to the carbohydrate content 
of the test meal (units insulin/g carbohydrates). Plasma glucose samples 
were taken before the meal and throughout the whole study period. 
Paper I. On the same day, we measured solid gastric emptying using 
scintigraphy of a 99mTc labelled standard meal for three hours and followed 
emptying by fluoroscopy of ROM (non-digestible solids; 20 spherical 
radiopaque markers) added to the meal 4-6 h after meal intake. The 
fluoroscopy measurement of ROM was followed each hour for three hours 
or until all the ROM were emptied. The number of ROM in the stomach was 
counted each hour after meal intake. We focused on the time period 4–6 h 
after meal intake to test for delayed gastric emptying of ROM since 
indigestible solids or ROM   are emptied with a time delay of 1.5–2 h 
relative to digestible solids (106).  
Paper II. Before the study, gastric emptying was confirmed using a 
scintigraphic method. The ingestion time of the test meal of food in LP was 
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25 minutes. Plasma glucose was followed for three hours from the 
beginning of the meal.  
Paper III. The subjects arrived at the hospital at 11.15 am after ingesting a 
standard breakfast at 07.30 am and a snack at 9 am. The study started at 
noon. Insulin-dependent DM patients with suspected gastroparesis took 
their ordinary dose of regular human insulin for lunch (units insulin/g 
carbohydrates) 30 minutes before the meal. Plasma glucose before the 
meal was ≤ 10.0 mmol/L. In random order, the subjects ingested solid 
meals with a LP and SP. Ingestion time was up to 25 minutes. Gastric 
emptying was followed by scintigraphy for three hours from the beginning of 
the meal. Plasma glucose and insulin were followed throughout the study 
period. 
Paper IV. Insulin-treated DM subjects with confirmed gastroparesis were 
randomised to receive dietary advice, which differed regarding the particle 
size of the food (for more detailed information, see appendices). Otherwise 
the nutritional composition in the two dietary treatment groups was the 
same and in line with the recommendation for diabetic patients (126), with 
the exception of the recommendation that the fat content was reduced to 
25-30% of total energy and the fibre content to 15 gram/1000 kcal 
according to Paper III, and in order to remain in line with the current 
recommendations for patients with gastroparesis (109). The study period 
was 20 weeks.  
The subjects were also randomised to one of two dieticians, who provided 
the dietary advice, and they received dietary counselling on seven 
occasions. Both groups were advised to have the same meal schedule: 
breakfast, snack, lunch, snack, dinner and evening snack. 
GI symptoms, quality of life, anxiety and depression were assessed at 
baseline and on completion of the study. The subjects completed the 
questionnaires: PAGI-SYM (127, 128), GCSI (129), Short-Form Health 
Survey (SF36) (130) and Hospital Anxiety and Depression Scale 
(HADS)(131). Nutritional intake was investigated at baseline and on 
completion of the study by keeping a four-day dietary record at home. One 
dietician provided the subjects with instructions regarding the 
questionnaires and dietary recording. Any ambiguities were resolved when 
the questionnaires and dietary records were returned. The same dietician 
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calculated the nutrient content in all dietary records from the Database 
Swedish National Food Composition Tables, 11th of April 2007 (National 
Food Agency, Uppsala, Sweden) using the computer program Dietist XP 
version 3.2, (Diet and Nutrition Data, Bromma, Sweden).The energy 
content (kcal), and the amount of protein, fat, carbohydrates and fibre (all in 
grams) were used.  
Body mass index (BMI) was calculated at baseline and on completion of the 
study. Blood samples were taken at baseline and on completion of the 
study for analyses of glycosylated haemoglobin (HbA1c) were converted to 
the Diabetes Control and Complications Trial (DCCT), standard levels using 
the formula: HbA1c (DCCT) = (0.923 x HbA1c (MonoS) + 1.345; R2 = 0.998) 
(132).  
 
 
Figure 2. Flow chart for Paper IV. 
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Methods                                                                                                                         
Measurement of gastric emptying using a scintigraphic technique 
(Paper I).  
Assessment of gastric emptying using gastric scintigraphy was registered 
for three hours in a fasting condition. A gamma camera registered one 
mean value every 5 minutes for 180 minutes. The gamma camera 
registered gamma radiation from 99mTc in anterior and posterior views of the 
stomach, mean value for three minutes followed by a pause for two 
minutes. The test meal was according to Swedish standard (133) and 
reference values were used (134). The nutrient content of the test meal, 
based on eggs, was 310 kcal, 19 g protein (25% of the total energy), 18 g 
fat (52 % of the total energy), and 17 g carbohydrates (23 % of the total 
energy) and 150 g water.  
Comments. Because gastric emptying using scintigraphy is the worldwide 
'gold standard', this method was also our choice. The energy percentage of 
fat was high in this meal, contrary to what is proposed to be used as the 
initial screening test for gastric emptying in the consensus of the American 
Neurogastroenterology and Motility Society and the Society of Nuclear 
Medicine, U.S. (86). However, it is suggested that in some patients a low-
fat, egg white meal may not prove to be an adequate functional challenge, 
especially for patients who report symptom exacerbations after eating lipid-
rich diets. These subjects probably need a high-fat meal (86).  
In our papers, separate reference values are presented for men and women 
before and after the menopause. Because gastric emptying in females is 
slower than in men and women before menopause have a lower gastric 
emptying rate, it is important to have different reference values for women 
(134). For the most part, certain time points have been used to evaluate 
gastric emptying: the time until gastric emptying begins after a finished meal 
(lag phase), the time point after a finished meal for emptying 50% of the 
isotope (T50) and/or percentage isotope remaining in the stomach at time 
point 120 minutes from the finished meal (R120 or T120). For diagnosis, T50 
and/or R120 or T120 are most widely used. In this study, the measurement T50 
could not be used because not all subjects had emptied 50% of the 
radioactivity from the ventricle during the study period (3 h). R120 has 
therefore been used to establish a diagnosis of gastric emptying. We 
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measured gastric emptying for three hours and not four hours as advocated 
in the literature (86). Abell et al. suggest measurements 1, 2, 3 and 4 hours 
after finishing the meal. The choice of three hours measurement only in our 
study was because the subjects were in a sitting position during the whole 
test, not just at four time points as recommended (86). It is very difficult to 
be in a sitting position for three hours and we considered four hours 
impossible. 
Gastric emptying by radiopaque markers (Paper I).  
To assess gastric emptying of ROM we used fluoroscopy and counted the 
number of ROM remaining in the stomach 3,4, 5 and 6 h after meal intake, 
which is a standard method used at our hospital (106).  
Comments. Measurement of gastric emptying with ROM using fluoroscopy 
has been compared to gastric scintigraphy in healthy individuals and in a 
small group of patients with DM. This validation revealed a significant 
correlation between the methods (106). One of several reasons that 
gastroparesis is under-recognised and inadequately investigated is poor 
access to scintigraphy. However, as fluoroscopy is available at all hospitals, 
emptying of ROM could serve as a screening method for delayed gastric 
emptying. This method has also been suggested as being a better means 
of detecting gastroparesis compared to scintigraphy (135). However, results 
with a lower correlation also exist (136). No comparison has been made 
between gastric emptying with ROM and scintigraphy in a large group of 
gastroparetic subjects. We therefore wanted to validate the method in 
gastroparetic patients. 
Gastric emptying by scintigraphic technique (Paper III).  
Gastric emptying was performed in a sitting position with the gamma 
camera positioned behind the subjects throughout the whole study period 
(0–180 minutes). The gamma camera registered the mean value every 
second minute throughout the 180 minutes. Gastric emptying was 
measured using two test meals. They consisted of 100 g of meat, 40 g of 
pasta, 150 g of carrot and 5 g of canola oil. The nutrient content was 375 
kcal (1.57 MJ), 26 g protein, 13 g fat (31% of the total energy), 38 g 
carbohydrates and 4.8 g of fibre (3 g/MJ), calculated using the National 
Food Composition Tables (137). The only difference was the particle size. 
Pasta was chosen because it has a low glycaemic index, which is preferred 
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in a DM diet (138, 139). Five Mega Becquerel (MBq) of the tracer 99mTc 
were added to the uncooked pasta. Supplementary pictures 1-3. 
Comments. Because the relationship between the different particle sizes 
and gastric emptying was being studied, it was not possible to use any 
standard test meal for the scintigraphic method (133), and reference values 
were therefore not available. Gender, age and BMI-matched healthy 
subjects were therefore included as references for normal gastric emptying 
rate. 
 
 
Supplementary picture 1. Ingredients: carrot, meat and pasta 
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Supplementary picture 2.Test meal with large particle size 
 
Supplementary picture 3.Test meal with small particle size 
Plasma glucose response after a solid test meal (Papers I, II and 
III).     
In Paper 1, plasma glucose was taken at the beginning of the meal (00), at 
the end of the meal (0), and after 15, 30, 45, 60, 90, 120, 150, 180, 210, 
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240, 270, 300, 330 and 360 minutes, or until all ROM had emptied from the 
stomach. In Paper II, blood samples were taken before the meal (0) and 
after 15, 30, 45, 60, 90, 120, 150, 180 minutes. In Paper III, the first blood 
sample was taken at the beginning of the LP and SP meal and then every 
15 minutes throughout the whole study period of 180 minutes. Plasma 
glucose samples were analysed immediately in an automated plasma 
glucose analyser using a glucose oxidase method (Merck, Darmstadt, 
Germany) using HemoCue NAD-NADH (HemoCue AB, Ängelholm, 
Sweden). 
Comments. If the postprandial glucose correlated with gastric emptying, this 
measurement should be a very cheap and widely available screening 
method for gastroparesis. Every diabetic team could take plasma glucose 
samples and thus have a cheap tool at their disposal.  
During the testing in Paper II, the subjects were in a sitting position and 
were not allowed to walk around as it can affect both gastric emptying (140) 
and plasma glucose response. They only walked to the toilet close to the 
test room. In Paper III, the subjects were in a sitting position the whole time.  
Metabolic control (Papers I, II, III and IV)                                                                                 
HbA1c was converted to the Diabetes Control and Complications Trial, 
standard levels using the formula: HbA1c (DCCT) = (0.923 x HbA1c 
(MonoS) + 1.345; R2 = 0.998) (132).  
Comment. To assess the metabolic control HbA1c was analysed in all 
studies as it reflects the metabolic control during 8-12 weeks (17, 141). The 
glycosylated haemoglobin (HbA1c) is presented according to the Diabetes 
Control and Complications Trial standard. 
Measurement of insulin concentration (Paper III)                                                        
The insulin concentration was analysed every 15 minutes for 0 -180 
minutes. The serum insulin samples were centrifuged and stored at -20ºC 
until analysis. The insulin levels were determined using a radio 
immunochemical RIA assay technique (Diagnostic Products Corporation, 
Los Angeles). 
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Comment. The insulin concentration has an impact on the postprandial 
glucose curve. To sort out the impact of gastric emptying on postprandial 
glucose, the impact of insulin concentration and gastric emptying needs to 
be differentiated.  
Gastrointestinal symptoms (Papers I, II and IV)                                                                   
The severity of GI symptoms were assessed using PAGI-SYM  (Appendix 
3) and GCSI. PAGI-SYM is developed to evaluate symptom severity during 
the preceding two weeks. The 20-item PAGI-SYM includes six subscales: 
heartburn/regurgitation, fullness/early satiety, nausea/vomiting, bloating, 
upper abdominal pain and lower abdominal pain, analysed on a 6-point 
Likert scale ranging from 0 (no symptoms) to 5 (very severe symptoms). 
PAGI-SYM has good reliability, responsiveness and evidence supporting 
construct validity in subjects with GERD, dyspepsia or gastroparesis (127). 
The Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD), which 
is a part of PAGI-SYM, consists of nine items with three subscales – 
fullness/early satiety, nausea/vomiting and bloating – has demonstrated 
excellent test-retest reliability and good validity and responsiveness to 
treatments for gastroparesis (142).  
Comments. GI symptoms occur in some patients with gastroparesis, 
although there are gastroparetic patients without GI symptoms. To optimize 
treatment and management, it is important to detect how often patients are 
asymptomatic, and to find out which symptoms most often correlate with 
gastroparesis. PAGI-SYM is suitable for this as it has been validated and 
used in studies with gastroparetic patients (66, 143). 
Anxiety and depression (Paper IV).  
The severity of anxiety and depression were determined using the self-
reporting questionnaire Hospital Anxiety and Depression Scale (HADS) 
(Appendix 4) (131, 144, 145). HADS contains 14 items, seven items on 
anxiety and seven items on depression. Patients score the extent to which 
they agree with each statement on a four-point scale, ranging from 0 to 3. 
Cut-off points for severity in each domain are the scores: 0–7 = normal, 8–
10 = mild, 11–14 = moderate and 15–21 = severe. A score of 8 or above is 
considered abnormal. The HADS questionnaire has been reported to have 
good validity in DM subjects (145). Factor structure, discriminant validity 
and internal consistency were studied in a review paper and the authors 
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found that the sensitivity and specificity for detecting anxiety and 
depression were 0.80 (144).  
Comment. HADS has previously been used in DM patients with 
gastroparesis and found to be useful in this patient group (67). 
Quality of life (Paper IV) 
The 36-item Short-Form Health Survey (SF-36) was used to evaluate 
quality of life(Appendix 5) (146, 147). SF-36 consists of eight different 
domains and these can be summarised in a physical component summary 
(PCS): physical functioning, role physical, bodily pain and general health; 
and a mental component summary (MCS): vitality, social functioning, role-
emotional and mental health. The highest score possible is 100, where no 
limitations or disabilities are reported, and the lowest score possible is 0, 
where the greatest degree of limitation or disability is reported. 
Comments. SF-36 is a general questionnaire and is not disease specific. It 
has been used in many studies in different diseases and in health surveys 
in the general population. This makes it possible to compare the quality of 
life in different groups of patients.  
Dietary intake (Paper IV) 
The subjects kept four-day dietary diaries at home. Three weekdays and 
one weekend day were chosen. The amounts of all food and beverages 
were recorded in weight and household measures. The nutrient content 
was calculated in all dietary records using the Database Swedish National 
Food Composition Tables, April 11, 2007 (148) and the computer program 
Dietist XP version 3.2, (Diet and Nutrition Data, Bromma, Sweden). For this 
paper, the caloric content (kcal), and the amount of protein, fat, 
carbohydrates and fibre (all in grams) were calculated.  
Comments. Methodological error was minimised by the same dietician 
providing instructions on how the dietary diary should be kept. This dietician 
interviewed each subject and any ambiguities were resolved when the 
dietary records were returned. The same dietician thereafter calculated the 
nutrient content in all dietary records to reduce variability in the 
assessment. 
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Nutrition status (Paper IV)                                                                                                
Body weight was recorded with the person in their underwear and without 
shoes to the nearest 0.1 kg. Calibrated, electronic scales were used (Serial 
no 11087, system 31, Advanced Weighing Co Ltd, New Haven, East 
Sussex, BN9 0DU, UK). Height was measured in a standing position to the 
nearest 0.5 cm. Body mass index (BMI) was calculated as weight (kg) 
divided by height squared (m2) (kg/m2). 
Comment. In the literature, it is suggested that gastroparetic DM subjects 
have nutritional deficiencies (56). Therefore we considered BMI to reflect 
energy intake. 
Statistical analysis                                                                                                     
Statistical evaluations were performed using the statistical software 
package IBM SPSS/ PC statistics 19 (Chicago, IL, US).  
Results are generally presented as median and range, unless otherwise 
noted. Correlations were calculated using Spearman's correlation 
coefficients. Nominal data were compared by using the Pearson’s Chi-
squared test. Comparisons between groups were made with the Mann-
Whitney U-test. 
In Papers I and II, the sensitivity, specificity and positive and negative 
predictive value were estimated in order to diagnose gastroparesis with 
gastric scintigraphy being the gold standard. In Paper I, these were 
analysed using ROM emptying at different time points. In Paper II, a 
receiver operating characteristics (ROC) curve was used to determine 
sensitivity and specificity of upper GI symptom severity (GCSI) and 
postprandial glucose parameters to make a diagnosis of gastroparesis, 
again with scintigraphy being the gold standard. An area under the ROC 
curve (AUROC) of >0.7 is considered to be fair, >0.8 is considered to be 
good and >0.9 is considered to reflect excellent discriminating ability. The 
best cut-off values for discriminating between patients with and without 
gastroparesis were determined.  
In Paper II a mixed between-within subjects analysis of variance (ANOVA) 
was conducted to assess the effect of delayed gastric emptying, i.e. 
gastroparesis, on postprandial glucose response across the three-hour 
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period after intake of the test meal. Postprandial plasma glucose response 
is also presented as the maximum increase in plasma glucose after meal 
intake (peak glucose response) and the time to reach the peak glucose 
value after meal intake, and these parameters were compared between 
patients with and without gastroparesis. 
In both Papers II and III the incremental area under the curve (IAUC) of the 
postprandial glucose values was calculated using the trapezium rule (149).  
In Paper IV, the demographic characteristics of the patients and the 
outcome variables at baseline and after the treatment period in the two 
groups are shown as mean ± SD and median (range). For comparisons 
within the groups, the Wilcoxon Signed Rank test was used and 
comparisons between the groups for outcome variables were made using 
Analysis of Covariance (ANCOVA), adjusting for baseline values, and the 
between-group differences in changes in the outcome variables are shown 
as a mean and 95% CI. In all papers statistical significance was accepted at 
p < 0.05.  
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Results 
Paper I 
We included 115 subjects with insulin-treated DM (56 men, 59 women, 
median age 53, range 21-69 years) and all patients completed the 
investigation. Of these, 72 were referred to our unit for evaluation of 
suspected gastroparesis and 43 were recruited from a trial aimed at 
assessing GI symptoms in patients with insulin-treated diabetes. On clinical 
grounds, the principal investigator (EO) suspected that 99 of the patients 
suffered from delayed gastric emptying. The subjects were grouped into two 
main DM groups. In the type 1 DM group, we included 78 subjects with type 
1 DM, three patients with Latent Autoimmune Diabetes in the Adult (LADA) 
and one subject with secondary diabetes (caused by pancreatitis). Included 
in the type 2 DM group were 31 subjects with type 2 DM, one with Maturity 
Onset Diabetes in Young (MODY) and one with secondary diabetes caused 
by corticosteroid medication. The characteristics of the subjects are shown 
in Table 1.  
The plasma glucose level was median 8.3, range 4.0–10.0 mmol/L at the 
beginning of the test meal. During the test meal, the lowest plasma glucose 
value was 3.0 mmol/L and the highest value was 17.2 mmol/L. The plasma 
glucose level during the first three hours of the test was 8.5, 4.7–13.1 
(median, range) mmol/L and 8.3, 4.7–13.1 mmol/L during the entire test (six 
hours). Ten subjects needed glucose supplementation during the study 
because of a plasma glucose level below 4 mmol/L.  
The correlation between gastric emptying using a scintigraphic method at 1, 
2 and 3 hours and ROM by fluoroscopy at 3, 4, 5 and 6 hours was 0.41 to 
0.54, (p <0.0001). (Figure 3 and Table 2). 
Eighty-three (72%) patients had a delayed gastric emptying rate using the 
scintigraphic technique (delayed emptying at 2 hours), whilst 29 (25%) 
patients had delayed emptying of ROM at 6 hours. Of the 29 patients with 
delayed gastric emptying of ROM, 28 also had delayed scintigraphic 
emptying, whereas 55 of the patients with a normal ROM test (total 86 
patients) had delayed gastric emptying with scintigraphy, indicating poor 
sensitivity (34%) and negative predictive value (36%) of ROM emptying and  
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Table 1. Characteristics of the subjects with type 1α and type 2γ diabetes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
α Type 1 diabetes: type 1 diabetes, LADA= Latent Autoimmune Diabetes in the Adult and 
secondary (pancreatitis) diabetes                                                                                                                                                                     
γType 2 diabetes: type 2 diabetes, MODY=Maturity Onset Diabetes in Young diabetes and 
secondary (cortisone) diabetes                                                                                                                                                               
GFR=glomular filtration rate, HbA1c=glycosylated haemoglobin                                                                                 
*p=0.034, ** p=0.006, *** p=0.001, **** p<0.0001 
 
high specificity and a positive predictive value of 97% for both in diagnosing 
gastroparesis. An alternative definition of abnormal ROM  emptying 
retention (5 hours and/or 6 hours) resulted in higher sensitivity (40%) but at 
the expense of reduced specificity (94%). Other alternative definitions of 
abnormal gastric emptying of ROM yielded lower sensitivity, specificity and 
positive and negative predictive value. 
Both upper and lower GI symptoms were reported frequently by the 
patients. The median (range) subscale scores of PAGI-SYM were: 
nausea/vomiting 0.67 (0-5), fullness/early satiety 2.0 (0–5), bloating 2.5 (0–
5), upper abdominal pain 2.0 (0–5), lower abdominal pain 1.0 (0–5), and 
heartburn/regurgitation 1.3 (0–4.9) (Figure 4). The strongest correlations  
 
 Type 1 diabetes, n=82 Type 2 diabetes, n=33 
 Median Range Median Range 
Age, year 50*** 21-69 63*** 27-69 
Weight, kg 77.1*** 48.7–124.5 92.4*** 56.5–114.5 
BMI, Kg/m2 26.0**** 18.4 –38.0 31.0**** 18.6–40.9 
Duration of diabetes, year 30**** 2-63 17**** 2-40 
Insulin treated, year 30**** 2-63 8**** 1-24 
U insulin/kg body weight 0.5** 0.1–1.3 0.8** 0.1–3.1 
Number of injections, n 4* 1 - 8 4* 1-6 
HbA1c, % 7.9 ns 4.2–10.1 7.8 ns 5.7–12.1 
HbA1c  5 years ago, % 8.1 ns 5.7–12.0 8.2 ns 5.8–11.7 
Creatinine, µmol/L 72 ns 51 - 140 81 ns 47 - 174 
GFR, mL/min/1.73 m2 88.5 ns 40 - 141 86 ns 34 - 144 
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Table 2. Correlation coefficients between gastric scintigraphy and 
emptying of radiopaque markers (ROM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
between gastric emptying and upper gastrointestinal symptoms were noted 
for scintigraphic emptying and nausea/vomiting (r =0.30; p<0.001) and 
postprandial fullness/early satiety (r =0.34; p<0.0001). No sum score was 
significantly associated with emptying of ROM. 
 
 
Figure 3. Association between retention of the radioactivity in the stomach at 120 min (R_120)   
 and number of radiopaque markers (ROM) at 6 h (ROM_6) after meal intake in 115 diabetic  
 subjects (r = 0.47; P < 0.0001). 
 
Comments. Plasma glucose ≤ 10.0 mmol/L was chosen as hyperglycaemia 
could decrease gastric emptying. The subjects arrived at the hospital in the 
morning in a fasting condition. This means that the subjects had not taken 
any insulin in the morning. During the morning, plasma glucose increases 
because of stress hormones, making it difficult to achieve plasma glucose 
 Scintigraphy 
Retention 1 hour 
Scintigraphy 
Retention 2 hours 
Scintigraphy 
Retention 3 hours 
ROM Retention    3 hours 0.42 0.45 0.41 
ROM Retention    4 hours 0.54 0.49 0.48 
ROM Retention    5 hours 0.44 0.45 0.48 
ROM Retention    6 hours 0.41 0.47 0.52 
ROM Retention  4-6 hours 0.53 0.52 0.52 
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of 4-6 mmol/L (150). Moreover, several of the subjects had travelled to the 
hospital for 2-3 hours during the morning before the test. When the subjects 
finished registration using a gamma camera, they were transported 
immediately in a wheelchair to the fluoroscopy equipment. This was done 
as walking has been shown to increase gastric emptying (140). The time 
between final registration by scintigraphy and the first fluoroscopy 
measurement was no more than five minutes. This means that we tried our 
best to remove potential confounders, but despite this the ROM test were 
only found to be moderately helpful in the clinical setting. However, a 
positive ROM test seems to be reliable, whereas a negative test is less 
reliable.   
 
Figure 4. Severity of GI symptoms in subjects with insulin-treated diabetes with and  
without gastroparesis. Distribution of PAGI-SYM summary scores (0–5); white 
represents the highest score (very severe symptoms), and with increasing darkness  
of the gray colour the severity of the symptoms decreases 
(darkest gray colour = no symptoms). 
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Paper II 
Forty-eight men and 35 women with insulin-treated DM were included in 
this study. They were recruited due to clinical suspicion of gastroparesis, 
such as GI symptoms and/or poor metabolic control. Of the subjects 
included, 55 had type 1 DM, 23 had type 2, three had LADA and two had 
secondary DM secondary to cortisone medication.  The subjects with DM 
type 1, LADA and secondary DM were treated with short-acting insulin, 
either lispro or aspart, and long-acting insulin, either glargin or detemir. The 
subjects with DM type 2 were treated with lispro, human insulin or aspart 
and human isophan, glargin, detemir insulin or mixed insulin. Gastroparesis 
was confirmed in 53 (64%) subjects, 29 (55%) of them were women and 38 
of them were in the DM type 1 group. Clinical characteristics of the patients 
obtained from a chart review are shown in Table 3, divided into groups with 
(n = 53) and without (n = 30) gastroparesis. 
The subjects tolerated the test meal well (Supplementary picture 2).The 
median ingestion time was 25.0 minutes (range 19-35). Median plasma 
glucose at the beginning of the meal was 7.5 mmol/L (range 4.3-10.0) in 
subjects with gastroparesis and 8.4 mmol/ L (4.9-10.0) in subjects without 
gastroparesis, which was not significantly different (p = 0.23). During the 3-
hour study period, 12 subjects with gastroparesis and one subject with 
normal gastric emptying needed glucose supplementation due to plasma 
glucose <4.0 mmol/L (range 6-36 g of glucose). No clinical hormonal 
counter regulation was detected in these subjects as their highest 
measured plasma glucose at 180 minutes was lower (8.7 mmol/L) than in 
all subjects (17.5 mmol/L). The plasma glucose value before glucose 
supplementation was used for the subsequent analyses (most recent data 
carried forward). 
The postprandial plasma glucose is illustrated in Figure 5, differentiated into 
subjects with and without gastroparesis. There was a significant difference 
between the groups in glucose response, p <0.0005. The incremental area 
under the curve (IAUC) and the peak level were lower in the gastroparetic 
group than in the group with normal gastric emptying. Peak time was the 
same for both groups (Table 4). A weak but significant correlation between 
the peak glucose response and gastric scintigraphic retention at two hours 
was seen (r = -0.23 (p = 0.04).  
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Table 3. Demographic charactaristics of diabetic subjects with and without gastroparesis.  
 Subjects with 
gastroparesis, n=53 
Subjects with normal gastric 
emptying, n=30 
 Median Range Median Range 
Age, year 54* 27-69 62 29-69 
Weight, kg 84.3 48.7-124.5 83.8 68.0-119.5 
BMI, Kg/m2 27.0 19.00-40.9 27.0 21.9-37.0 
Duration of diabetes, years 25 2-55 16 2-48 
Insulin treated, years 23 1-55 15 2-48 
U insulin/kg body weight/day 0.6 0.2-2.2 0.6 0.2-1.7 
Number of insulin injections/day, 
n 
4 1-8 5 2-7 
HbA1c, % ʃ  7.4    5.7-12.0  7.5  5.4-10.1  
Gastric scintigraphic retention at 
120 minutes, % 
74 55-91 38 17-62 
Creatinine, µmol/L 73 55-142 76 47-162 
GFR, mL/min/, 1.73 m2 85 43-128 88 37-141 
BMI = body mass index, GFR = glomerular filtration rate, HbA1c = glycosylated haemoglobin.  * p<0.05. 
ʃ= HbA1c the Diabetes Control and Complications Trial, standard 
The GI symptoms are presented in Table 4. GI symptoms were significantly 
more severe (p = 0.0001) in the gastroparetic group in comparison with the 
non-gastroparetic group. The correlation between severity of GI symptoms 
and retention at 2 hours using the scintigraphic method was also significant 
for all PAGI-SYM subscale scores (p = 0.001) (Table 5). Between the 
postprandial glucose variables (IAUC and peak glucose levels) and PAGI-
SYM subscale scores weaker correlations were noted (Table 5). 
GI symptom severity (GCSI total score) had the best discriminative validity 
in identifying patients with gastroparesis (AUROC = 0.85) with the optimal 
cut-off point being a GCSI total score of ≥0.8, yielding a sensitivity of 87% 
and a specificity of 80%. The positive and negative predictive values were 
88% and 77% respectively. The optimal cut-off point for the peak glucose 
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response increase in order to identify patients with gastroparesis was ≤1.8 
mmol/L, yielding a sensitivity of 60% and a specificity of 70%. 
Table 4. Postprandial glucose response after test meal and GI symptoms during 2 weeks 
according to PAGI-SYM in diabetic patients with and without gastroparesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PAGI-SYM = Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index.                          
IAUC=Incremental Area Under the glucose Curve.                                                                                                           
# Makes up the Gastroparesis Cardinal Symptom Index (GCSI) 
A combination of GCSI total score ≥0.8 and a peak glucose increase ≤1.8 
mmol/L resulted in a sensitivity of 37% but a specificity and a positive 
predictive value of 100%. All 20 patients who had this combination had 
gastroparesis. However, the negative predictive value was only 47%. If 
patients were allowed to have a GCSI total score of ≥0.8 and/or a peak 
glucose increase of ≤1.8 mmol/L, the sensitivity and specificity in identifying 
gastroparesis would be 87% and 67% respectively. 
 
 Diabetes with gastroparesis,  
n=53 
Diabetes without gastroparesis, 
n=30 
p value 
 Median Range Median Range  
IAUC  58 0–722 196 0.6-1101 0.018 
Time to peak glucose level (min)  45 15–180 60 15-180 0.30 
Peak glucose response (mmol/L)  1.3 -2.1–5.8 2.4 -0.3–8.8 0.011 
PAGI-SYM: Nausea/vomiting # 
 
1.00  
 
0.0-4.33 0.0  
 
0.0-2.33 
 
0.0001 
PAGI-SYM: Fullness/early satiety # 2.25  
 
0.0-5.00  
 
0.25  
 
0.0-4.25 
 
0.0001 
PAGI-SYM: Bloating # 3.00 
 
0.0-5.00  
 
0.0 
 
0.0-4.50 
 
0.0001 
 PAGI-SYM: Upper abdominal pain 2.00 
 
0.0-5.00 
 
0.0  
 
0.0-3.50 
 
0.0001 
PAGI-SYM: Lower abdominal pain 1.50  
 
0.0-5.00 
 
0.0 
 
0.0-4.0 
 
0.0001 
PAGI-SYM: Heartburn/regurgitation 1.00 0.0-3.14 0.0 0.0-4.14 0.0001 
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Table 5. Correlation between retention of the isotope in the stomach at 120 minutes after finished meal,                                                                                           
incremental area under the glucose curve, respectively and GI symptom severity (PAGI-SYM scores). 
 
 
Diabetic 
Subjects 
n =83 
 
PAGI-SYM 
nausea/ vomiting 
 
PAGI-SYM 
fullness/ early 
satiety 
 
PAGI-SYM 
bloating 
 
PAGI-SYM upper 
abdominal pain 
 
PAGI-SYM lower 
abdominal pain 
 
PAGI-SYM 
heartburn/ 
regurgitation 
 
R120 
 
r=0.60 
p< 0.0001 
 
r=0.62 
p<0.0001 
 
r=0.63 
p<0.0001 
 
r=0.55 
p<0.0001 
 
r=0.49 
p<0.0001 
 
r=0.64 
p<0.0001 
 
 IAUC 
 
r= -
 
0.32 
p=0.003 
 
r=-0.27 
p=0.02 
 
r=0.36 
p=0.01 
 
r=0.27 
p=0.05 
 
r=0.42 
p=0.000 
 
r=-0.22 
p=0.048 
 
Peak glucose 
level 
 
r=-0.30 
p=0.006 
 
r=-0.19 
p=0.088 
 
r=-0.26 
p=0.019 
 
r=-0.20 
p=0.071 
 
r=-0.30 
p=0.007 
 
r=-0.12 
p=0.26 
R120= retention of the isotope in the stomach at 120 minutes after finished meal. 
IAUC = incremental area under the plasma glucose curve. 
PAGI-SYM= Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index. 
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Figure 5. Plasma glucose response after a test meal (0-180 min) in diabetes patients 
presented with and without gastroparesis. A mixed between-within subjects ANOVA 
demonstrated a significant main effect of the diagnostic group, i.e. the plasma glucose 
response differed between patients with and without gastroparesis, with a blunted plasma 
glucose response in the gastroparetic group (p=0.005). 
Comments. The gastroparetic patients demonstrated a blunted postprandial 
glucose response and this in combination with the presence of GI 
symptoms seem to be of potential usefulness in the clinical setting raising a 
suspicion of delayed gastric emptying in diabetic patients. 
Paper III 
Seven subjects with insulin dependent DM and gastroparesis were included 
in the study. The characteristics of the seven subjects are shown in Table 6. 
Gastroparesis was determined by gastric scintigraphy in according to the 
criteria set by Stotzer et al. (106) in one subject before the study. They had 
no insulin pump and had not undergone surgery for gastrointestinal 
disease. Women of fertile age, and smokers were excluded. Seven healthy 
subjects were recruited from an advertisement in a newspaper. They were 
matched with the diabetic subjects for gender, age and BMI. All subjects 
tolerated the test meals well. 
p=0.005 
0 
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Tracer added to the test meal 
Before each meal was served, the pasta was incubated with 99mTc for three 
hours and shaken at + 37ºC in artificial gastric juice. As a result, 87.0 ± 
2.0% of the pasta in the SP meal and 87.4 ± 1.8% of the pasta in the LP 
meal were tagged. 
 
Gastric emptying 
In the DM subjects, the gastric lag phase was 15.1 ± 3.7 minutes for the LP 
meal and 1.4 ± 0.8 minutes for the SP meal (p = 0.028). In the control 
group, the gastric lag phases were 7.1 ± 3.9 minutes and 0.9 ± 0.6 minutes 
respectively, which did not differ significantly (Figure 6). 
After an SP and LP meal, T120 in the DM subjects was 31.6 ± 4.3% and 72.3 
± 4.9% respectively (p = 0.018). This statistical difference was the same at 
T180 (R180). In the control group after an SP and LP meal, T120 (R120) was 
17.9 ± 6.7% and 47.8 ± 3.5% respectively. Between the groups of subjects, 
T120 (R120) was significantly slower after an LP meal in the DM subjects (p = 
0.018) but not after an SP meal (p = 0.09).  
 
Blood glucose  and serum insulin response 
Blood glucose was 7.2 ± 1.1 mmol/L before the SP meals and 8.1 ± 0.5 
mmol/L before the LP meals (p = 0.44) in the DM subjects. A significantly 
greater (p = 0.018) IAUC for blood glucose was found in DM subjects after 
the SP meal compared to after the LP meal (Figure 7). In the DM subjects, 
the correlation coefficient between the retention of the SP meal in the 
stomach and the glucose response at 180 minutes was r = 0.82. 
There were no significant differences between the plasma insulin 
concentrations in DM subjects at 0 minutes before the SP meal and LP 
meal. 
Comments. The stomach grinds the diet into small particles 2 mm in size 
and gastric emptying begins. The study design was therefore performed 
with two equal meals with only one difference, the particle size. The 
hypothesis was that small particles would leave the stomach easier. Pasta  
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Table 6. Demographic charactaristics of diabetic subjects with gastroparesis and healthy control 
subjects. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are presented as means ± S.D. 
a Serum creatinine, reference value 60–120 mmol/L. 
b Orthostatic hypotension, decrease of systolic blood pressure, BP, was ≥30 mmHg.  
was chosen because of its low glycaemic index, which is recommended in a 
diabetic diet (126). 
The study was performed at noon as it is very difficult to achieve an 
euglycaemic glucose level in the morning in insulin-sensitive subjects, such 
as type 1 DM (150). It is confirmed that MMC phase III is often 
absent/infrequent in gastroparetic subjects (78, 151). This means that the 
stomach is not always empty in the morning. The subjects were therefore 
instructed to have a standard breakfast and snack before the test. At the 
 Diabetic subjects  
 
Healthy subjects 
Male/female (n) 3/4 3/4 
 
Age, year 
59.3±9.3 59.3± 9.1 
BMI, kg/m2 23.4±2.2 23.5±1.9 
HbA1c, % 8.2±0.8 5.7±0.3 
Duration of disease, year 37±14  
Average daily insulin dose, U/d 35.9±5.6  
Serum Creatinine, mmol/La 110.7±32.5  
Urinary protein, mg/min 44.9±72.2  
Retinopathy, n 7  
Orthostatic hypotension,nb 4  
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Figure 6. Gastric emptying (mean W S.E.M.) of meals of  small particle size                                                                                                                                                                                
(SP, triangle symbols) and large particle size   (LP, round symbols) in diabetic                                                                                                                                                                    
subjects with gastroparesis  (open symbols) and healthy subjects (solid symbols)                                                                                                                                                                   
after correction for ingestion time. Gastric emptying was significantly slower (p=0.018)                                                                                                                                                          
after LP meal in diabetic group than in control group, but no significant difference                                                                                                                                                                     
after SP meal between the groups. 
 
Figure 7. Blood glucose response mmol/L (mean±S.E.M.) after meals with small particle size                                                                                                                                                        
(SP, triangle symbols) and large particle size (LP, round symbols)  in diabetic subjects with                                                                                                                                             
gastroparesis (open symbols) and healthy subjects (solid symbols).  Incremental area under                                                                                                                                                     
the curve for blood glucose (IAUC) was significantly greater (p=0.018) after SP meal than                                                                                                                                                            
LP meal in diabetic subjects. 
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same time, the subjects could adjust the glucose level, with a dose of 
insulin for breakfast, achieving a blood glucose level of ≤10 mmol/L at noon. 
In this study, the test meal was not supplemented with any beverage as it 
has been found that water with a meal increases the gastric emptying of the 
meal (152). 
Paper IV 
Of 83 diabetic subjects with insulin-treated DM and suspected 
gastroparesis who were invited to participate in the study, 72 chose to 
participate. Following investigation using gastric scintigraphy, gastroparesis 
was found in 58 subjects although two of these did not want to participate in 
the study. The remaining 56 subjects (36 women) were randomised to the 
treatment groups and to one of two dieticians (Figure 8). In the intervention 
group, 22 subjects had type 1 DM, five subjects had type 2 DM and one 
subject had Latent Autoimmune Diabetes in the Adult (LADA) diabetes. The 
control group consisted of 14 subjects with type 1 DM, 13 with type 2 DM 
and one subject with Maturity Onset Diabetes in Young (MODY) diabetes. 
The demographic and clinical characteristics of the randomised patients are 
presented in Table 7. 
During the treatment phase, one patient in the intervention group died and 
five patients left the control group prematurely because of a worsening of 
existing upper GI symptoms (n = 3), occurrence of new GI symptoms (n = 1 
after a visit to Africa) or without any specific reason mentioned (n = 1). 
These missing data were imputed from the previous assessment (baseline), 
using the most recent observation carried forward technique, and were 
included in the analysis. 
All GI symptoms, except for upper abdominal pain, improved significantly 
(lower PAGI-SYM scores) after the intervention diet (Figure 9A), whereas 
none of the GI symptoms improved after the control diet (Figure 9B). All the 
primary outcome variables improved significantly more after the intervention 
diet compared to the control diet; nausea/vomiting (-0.56 (-1.01- -0.11) 
(mean change difference (95% CI); p = 0.01), fullness/early satiety (-0.61 (-
1.14- -0.08); p = 0.02) and bloating (-0.86 (-1.48- -0.25); p = 0.006). 
Regurgitation/heartburn also improved after the intervention diet compared 
to the control diet (-0.51 (--0.94- -0.07); p = 0.02).  
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Figure 8. Flow chart demonstrating the number of patients in the different phases of the study. 
After the treatment period, the severity of anxiety (HADS) was reduced in 
the intervention diet group but not in the control diet group. However, the 
between-group comparison of change in the anxiety score was not 
significant (Table 8). 
Depression (HADS) and quality of life (mental and physical component 
summary of SF-36) remained unchanged in both groups (Table 8). The fat 
intake increased significantly in the intervention diet group but not in the 
control diet group, whereas within-group comparisons for total intake of 
calories, fibre, carbohydrates and protein remained unchanged in both 
groups without any between-group differences. No differences were seen 
between or within the groups regarding body weight or metabolic control 
(HbA1c). Supplementary pictures 4-11 show examples with meals in SP. 
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Table 7. Demographic and clinical characteristics of subjects with insulin treated diabetes and gastroparesis presented as mean ± SD and 
median (range). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 R
120
=Retention of the radioactivity in the stomach 120 minutes after meal intake (gastric scintigraphy) 
R
180
=Retention of the radioactivity in the stomach 180 minutes after meal intake (gastric scintigraphy) 
GFR = glomerular filtration rate 
 
 
 
 
  
Age, years 
 
Duration of 
diabetes, 
years 
I   
 Insulin         
treated, years 
 
Insulin/kg 
body 
weight, U 
 
Body weight, 
kg 
 
BMI, kg/m2 
 
S-
Creatinine, 
µmol/L 
 
GFR,   
mL/min/ 
1.73 m2 
 
R120, % 
 
R180, % 
Intervention 
diet, n=28 
51.5 ± 11.7 
51 (31-69) 
28.25 ± 14.8 
28.0 (2.0-
65.0) 
    23.7 ± 15.8  
    28 (4- 46) 
0.6 ± 0.3 
0.5 (0.3-
1.7) 
77.9 ± 16.0 
74.65 (52.3 – 
110.3) 
25.6 ± 4.7 
25.0 (20.1-
40.9) 
82.2 ± 20.5 
76.5 (55-
138) 
80.0± 18.8 
82.5 (40-
126) 
77.1 ± 9.8    
79.5 (53 – 91) 
57.8 ± 16.4    
6  61 (18 – 81 ) 
Diabetes 
diet, n=28 
55.0 ± 11.4 
54.5 (27-
69) 
23.6 ± 15.6 
18.0 (2.0-
64.0) 
     21.6  ± 17.4 
     16 (1-63) 
0.7 ± 0.5 
0.5 (0.2-
2.2) 
78.4 ± 15.8 
80.8 (54.6 – 
114.4) 
27.7 ± 4.9 
28.4 (18.4-
36.0) 
72.2 ± 12.3 
74.0 (54-
100) 
82.7 ± 19.2 
86 (48-128) 
74.7 ± 12.9 
72.5 (55 – 94) 
59.9 ± 19.7 
5  55.5 (31 – 91) 
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Table 8. Variable at baseline and at finished 20 weeks study period grouped in intervention and control group, mean ± SD, median (range). The 
variables change within the group and between the groups, mean, 95% Confidence interval.  P < 0.05. 
 
BMI=Body Mass Index, HbA1c = glycosylated haemoglobin, DCCT standard, HADS= Hospital Anxiety and Depression Scale,                                                                             
PAGI-SYM=Patient assessment of upper gastrointestinal symptom severity index, SF36=The Short Form (SF36) Health Status Survey,                                                                
SF-36: PCS=Physical health, SF36:MCS=Mental health                                                                                                                                                                                    
R
120
=Retention of the radioactivity in the stomach 120 minutes after meal intake (gastric scintigraphy) 
R
180
=Retention of the radioactivity in the stomach 180 minutes after meal intake (gastric scintigraphy) 
GFR = glomerular filtration rate 
 Intervention diet, n=28 Diabetes diet, n=28 P value  
I/D diet  
Diff change 
mean, 95CI  
 
 Base line 
mean±SD 
median(range) 
Finished study 
mean±SD 
median(range) 
Change 
mean±SD 
median(range) 
p 
value 
Base line 
mean±SD 
median(range) 
Finished study 
mean±SD 
median(range) 
Change 
mean±SD 
median(range) 
p 
value 
  
Body weight, 
kg 
78.4 ± 16.3 
75.5 (54-112.4) 
77.9 ± 16.0 
74.7 (52.3-
110.3) 
-0.5 ± 3.6 
0.6 (-13.9-3.9) 
ns 79.0 ± 15.6 
82.0 (54.5-111.0) 
 
78.5 ± 15.8 
80.8 (54.6-114.4) 
-0.5 ± 2.2 
-0.7 (-5.0-3.8) 
ns 0.99 -0.012(-1.6-1.6) 
Kcal 1505 ±  462 
1480 (840-2893) 
1585 ± 483.1 
1507 (771-
3058) 
80 ± 385.0 
108 (-555-921) 
ns 1551 ± 423.1 
1574 (897-2893) 
1454 ± 319 
1469 (708-2153) 
-97 ± 417.9 
0 (-1392-488) 
ns 0.096 154 (28-336) 
 
Protein, g 65 ± 21.7 
61 (33-127) 
67 ± 17.9 
65 (41-118) 
1 ± 23.6 
0 (-63-55) 
ns 69 ± 19.6 
66 (39-127) 
65 ± 14.0 
65 (39-92) 
-5 ± 20.9 
4 (-83-25) 
ns 0.38 5 (-6 -15) 
Fat, g 60 ± 25.8 
55 (31-142) 
67 ± 27.6 
62 (28-162) 
7 ± 21.9 
4 (-58-49) 
ns 62 ± 23.9 
58 (29-142) 
57 ± 13.1 
55 (27-82) 
-5 ± 22.6 
0 (-70-24) 
ns 0.034 11 (1-20)   
Carbohydrate, 
g 
163 ± 48.9 
160 (78-269) 
166 ± 51.0 
166 (79-268) 
3 ± 48.3 
3 (-86-113) 
ns 162 ± 44.8 
153 (83-278) 
149 ± 47.7 
141 (64-253) 
-13 ± 50.0 
2 (-134-69) 
ns 0.17 16 (-7-40) 
Fibre, g 17 ± 6.3 
15 (7-34) 
16 ± 5.5 
15 (9-33) 
-1 ± 6.7 
-1 (-21-11) 
ns 17 ± 6.2 
18 (7-33) 
17 ± 7.5 
16 (7-38) 
0 ± 6.0 
0 (-13-12) 
ns 0.53 -1 (-4 -2) 
HbA1c, % 7.4 ± 0.8 
7.3 (5.6-9.2) 
7.4 ± 0.8 
7.3 (5.2-9.01) 
-0.0 ± 0.5 
0.0 (-1.2-0.9) 
ns 7.9 ± 1.2 
8.1 (5.4- 9.8) 
7.8 ± 1.1 
7.9 (5.7-10.5) 
-0.2 ± 0.6 
0.0 (-1.3-0.7) 
ns 0.98 -0.0 (-0.3-0.3) 
HADS, 
anxiety  
7.8 ±  4.3 
8.0 (0-18) 
6.5 ± 4.7 
6.0 (0-21) 
-1.3 ± 2.7 
-2.0 (-5.0-4.0) 
0.024 7.2 ± 4.6 
7.0 (1-17) 
6.4 ± 4.4 
6.5 (1-21) 
-0.8 ± 3.4 
0.0 (-10.0-5.0) 
ns 0.63 -0.4 
(-2.0-2.0) 
HADS, 
depression 
6.3 ± 4.9 
4.5 (0-17) 
5.6 ± 5.4 
3.5 (0-21) 
-0.6 ± 2.5 
-0.5 (-8.0-4.0) 
ns 6.6 ± 4.6 
5.0 (1-19) 
5.9 ± 4.8 
5.0 (0-21) 
-0.7 ± 4.2 
0.0 (-12.0-8.0) 
ns 0.99 -0.0 
(-1.8-1.8) 
SF-36: PCS 39.0 ± 11.4 
39.2 (7.4-55.3) 
40.2 ± 10.9 
39.4 (19.4-
59.5) 
1.2 ± 8.0 
0.9 (-18.3-20.3) 
ns 37.6 ± 12.0 
37.4 (13.1-55.3) 
35.5 ± 12.8 
32.9 (8.7-55.5) 
-2.1 ± 9.2 
-1.2 (-21.9-
16.7) 
ns 0.11 3.6 (-0.8-8.0) 
SF-36: MCS 41.5 ± 15.9 
39.9 (10.5-71.0) 
43.8 ± 15.2 
47.3 (9.7-62.2) 
2.3 ± 15.0 
2.8 (-50.4-26.6) 
ns 42.1 ± 13.3 
46.8 (7.5-56.6) 
41.5 ± 14.8 
42.0 (8.9-66.1) 
-0.5 ± 10.9 
0.6 (-32.0-20.4 
ns 0.48 2.6(-3.8-9.0) 
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Figure 9A. GI symptom severity, as measured with PAGI-SYM, at baseline and after the 
dietary  treatment period (20 weeks) in the group who received advice to eat the intervention 
diet (small particle size).                                                                                                                                                                                    
PAGI-SYM domains: N/V = nausea/vomiting; Fullness = fullness/early satiety;                                                                                                                                                                    
U / L abd pain = Upper / Lower Abdominal Pain; H/R = Heartburn/regurgitation.                                                                                                                                                                          
* p<0.05, ** p<0.01, *** p<0.001 vs. baseline. 
 
Figure 9B. Figure 2. GI symptom severity, as measured with PAGI-SYM, at baseline and after 
the dietary treatment period (20 weeks) in the group who were instructed to follow the control 
diet (B).                                                                                                                                                                                     
PAGI-SYM domains: N/V = nausea/vomiting; Fullness = fullness/early satiety;                                                                                                                                                                 
U / L abd pain = Upper / Lower Abdominal Pain; H/R = Heartburn/regurgitation.                                                                                                                                                                    
* p<0.05, ** p<0.01, *** p<0.001 vs. baseline.  
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Supplementary picture 4. Fish pâté, boiled potatoes and pepper sauce. 
 
Supplementary picture 5. Meatloaf and mango sauce. 
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Supplementary picture 6. Vegetable pâté 
 
   Supplementary picture 7. Yellow chicken soup.                               
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Supplementary picture 8. Steamed plaice, boiled potatoes, lemon- and 
squash sauce.                              
 
Supplementary picture 9. Mixed peach and strawberry. 
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Supplementary picture 10. Fruit salad 
 
Supplementary picture 11. Ice cream and raspberry sorbet 
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General discussion  
In the present thesis, I have demonstrated that gastric emptying of ROM 
and plasma glucose response after a standardized test meal can add 
information in the clinical management of DM patients, but cannot replace 
the current gold standard to diagnose gastroparesis, gastric scintigraphy. 
Moreover, a meal with SP increases the gastric emptying rate and 
reduces the postprandial blood glucose dip in Type 1 DM subjects with 
gastroparesis. In line with this, dietary treatment with SP significantly 
improves the key symptoms of gastroparesis in patients with DM.    
In Paper I, we noted a moderate association between gastric emptying of 
digestible solids, measured using gastric scintigraphy, and gastric 
emptying of indigestible solids, measured using ROM. The difference in 
results between the methods could be due in part to the fact that the 
methods do not measure exactly the same variables. However, based on 
our results it seems as if gastric emptying with ROM, using fluoroscopy 
could be used as a screening method for gastroparesis. If the 
measurement shows delayed emptying at 6 h, this is probably true. If the 
gastric emptying is normal but there is still a clinical suspicion question of 
gastroparesis, further investigation is required. The specificity and positive 
predictive value of the method were 97%, if ROM emptying at 6 h was 
used, but both the sensitivity and negative predictive value were clearly 
lower. In another study, emptying of ROM seemed to be very potent in 
predicting gastroparesis (135). The discrepancy between our study and 
Feldman et al. may be partly be due to different patient populations and 
potentially also different size of the markers.  
The correlation between GI symptoms and the gastric emptying rate was 
strongest for nausea/vomiting and postprandial fullness/early satiety when 
using a scintigraphic method, but there was no significant correlation with 
the fluoroscopy method in Paper I. 
Many factors are involved in gastric emptying, such as blood glucose level 
and a number of dietary factors. It is now well known that hyperglycaemia 
decreases gastric emptying. It is therefore important to have as normal 
plasma glucose as possible before and during the investigation. Chang et 
al. suggest a plasma glucose level of 4-10 mmol/L at the beginning of the 
test (85), which we used in our studies. It seems to be of great importance 
that departments measuring gastric scintigraphic emptying should have 
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equipment to measure plasma glucose, and as far as possible normalize 
the glucose levels before commencing and during the test.  A blood 
glucose level of 8 mmol/L decreases gastric emptying compared to 4 
mmol/L (53) although there is an increase in the gastric emptying at 2 
mmol/L (54). Hyperglycaemia is also known to inhibit the antral 
component of MMC phase III (90). Moreover, Jones et al. found that 
hyperglycaemia masks the medical effect of prokinetics (153). Based on 
these results we followed glucose levels carefully in our studies, and when 
needed normalized the levels in order to avoid the confounding effect of 
glucose levels on gastric emptying as far as possible.  
In Paper II the plasma glucose response was blunted in subjects with 
gastroparesis compared with subjects without gastroparesis. However, the 
GI symptom severity during the preceding two weeks was an even 
stronger predictor for gastroparesis than the plasma glucose response. 
In the literature, different correlations are presented between GI symptoms 
and gastric emptying and/or a diagnosis of gastroparesis (34, 36, 38, 55, 
68, 154). In Papers I and II, the correlation between these parameters 
was different. This could probably be caused by the inclusion criteria, 
since all subjects in Paper I had significant upper GI symptoms, but in 
Paper II also subjects with milder GI symptoms were included. Moreover, 
the proportion of subjects with normal gastric emptying was higher in 
Paper II than in Paper I, which could have an impact on the association 
between gastric emptying rate and GI symptom severity. Plasma glucose 
level before the test investigation the diagnosis was the same in both 
studies. Therefore the effect on gastric emptying and the diagnosis by the 
plasma glucose level was most likely the same in both studies. Moreover, 
Byzter et al. found in DM subjects in general that they had more severe GI 
symptoms when there was poor metabolic control (43). In Paper I and II 
HbA1c was not significantly different between the groups , ruling out 
differences in metabolic control as an explanation behind the discrepancy. 
In Paper III, the gastric emptying after SP meal was not significantly 
different in DM type 1 subjects with gastroparesis than in healthy subjects. 
However, after LP meal the gastric emptying rate was slower in subjects 
with gastroparesis than in healthy subjects. The IAUC of the plasma 
glucose response after SP meal in gastroparetic subjects was also 
significantly larger than after LP meal. These findings strengthened my 
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hypothesis that a meal with SP is beneficial for DM patients with 
gastroparesis, and this diet was then further tested in Paper IV.   
Up to now there has been no randomised trial of dietary interventions in 
gastroparesis and consequently there are no evidence-based 
recommendations (58). It has been advocated that the diet in diabetic 
gastroparesis should be low in fat and fibre (109). The test meals used in 
Papers II and III have a fat content of 31 energy per cent and 3 gram/MJ. 
The recommendation was 25-30 energy per cent fat and 27-30 gram fibre 
at the time Paper III was planned (155). Despite the fact that gastric 
emptying was more rapid after a test meal with SP in both gastroparetic 
subjects and in healthy controls, there was no significant difference in 
terms of gastric emptying rate between the groups after a meal with SP. 
However, gastric emptying after the LP meal was significantly slower in 
the patient group than in the healthy group. Both test meals were identical 
– only the particle size differed. The impact of different diet particle sizes 
ceased earlier, resulting in a significantly different gastric emptying rate 
(156). This means that fat and fibre content play a lesser role than particle 
size in gastric emptying; knowledge that we used in our controlled dietary 
intervention in Paper IV.  
Fat has a different impact on gastric emptying depending on whether the 
fat is in a liquid or a solid meal and when the fat was ingested. When fat 
was ingested in a liquid meal 30 minutes before a carbohydrate-containing 
solid meal, the lag phase was prolonged – the gastric emptying slope did 
not change in healthy subjects or in subjects with DM type 2. If fat was 
added to a solid meal and ingested immediately, the lag phase was short 
and the slope was reduced (112, 113). Often it has been suggested that a 
liquid meal should leave the stomach easier. However, Houghton et al. 
found that in young, healthy subjects a fat liquid meal caused the contents 
to move into the distal stomach, followed by redistribution of the contents 
in the distal stomach and then back into the proximal stomach in healthy 
subjects. When gastric emptying started, the contents moved down into 
the distal stomach again (111). In addition, the lag phase was prolonged 
and the slope decreased after a fat liquid meal. Based on these 
observations, other factors than merely the fat content per se should be 
considered when giving dietary advice to patients with delayed gastric 
emptying. 
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It can be noted that soluble fibre in a liquid and a solid meal may also not 
affect the gastric emptying rate in the same way. Bianci et al. studied 
gastric emptying after solid meals with 5 g of added soluble fibre. There 
were no significant changes in gastric emptying between the meals with 
and without added fibre in healthy subjects (157). Leiper et al. found that 
osmolality had a greater impact on gastric emptying than the viscosity of 
the meal (158). Insoluble fibre sometimes contributes to bezoars (115). It 
is therefore logical to decrease the fibre content in the diet for DM patients 
with gastroparesis. If the fibre is SP it may not form bezoars as diet with 
SP leaves the stomach more easily. On the other hand, there are many 
gastroparetic patients who suffer from constipation and a diet low in fibre 
could worsen the constipation (25). 
Other factors that have an impact on gastric emptying are the 
temperature, drinks with the meal and the volume of the meal. A meal with 
a temperature of <4ºC and >50ºC slows down gastric emptying (159). 
When a DM subject needs glucose due to hypoglycaemia, the usual 
advice is to take water with the glucose tablets. It is important that the 
drink is not too cold. The drink must then be warmed by the stomach 
before moving from the stomach into the duodenum. This will delay 
glucose absorption into the blood. The test meals in Papers II and III were 
served without a drink due to the fact that Thorsdottir et al. confirmed 
increased gastric emptying when 300 ml water was added to a meal 
compared to without (152). It has also been confirmed that a large meal 
volume delays gastric emptying in healthy subjects (160). Moreover, the 
meal size may be a problem specifically for patients with DM and 
neuropathy, as these patients have impaired relaxation of the proximal 
stomach after an ingested meal and this correlates with bloating (77). 
Therefore, taking the meal size into consideration when giving dietary 
advice to DM patients seems to be of importance. 
When assessing gastric emptying by means of scintigraphy, the lag phase 
and T50 and T120 (R120) are commonly used measures. When assessing 
insulin-treated gastroparetic patients, the duration of the insulin profile 
must be taken into account. Otherwise, reading the slope will be incorrect 
and the lag phase needs to be taken into account. The dietary intake also 
needs to match gastric emptying and plasma glucose with the specific 
profile of the insulin duration. 
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The aim behind dietary treatment of gastroparesis is to optimise metabolic 
control, decrease GI symptoms, improve nutritional intake and quality of 
life. In our study in Paper IV, a diet with SP improved GI symptoms, but no 
clear effects on metabolic control or quality of life were noted. 
In Paper IV HbA1c were not changed in any group. This could probably 
depend on 20 weeks being a too short study period, as HbA1c is a mirror 
of metabolic control for up to 12 weeks (141). On the other hand, the 
change is a process that takes place over time – and the patient needs 
time to learn the new diet. Studies with longer duration are needed in 
order to evaluate if diet with SP can affect the metabolic control in the long 
run.  
All upper GI symptoms except upper abdominal pain were improved in the 
intervention group, but not in the control group. There was a small 
increase in fat intake, but this did not result in gain in body weight, 
probably because of the short study period. It is interesting to note that in 
the intervention group, the GI symptoms improved, but not in the control 
group, even though they had not increased their fat intake. No other 
nutritional intake changes were noted in any of the groups. It may again 
depend on the short study period. GI symptoms in DM subjects generally 
is associated with psychological distress (161) and decreased quality of 
life (62). The GI symptoms, such as nausea, vomiting, bloating, abdominal 
pain, fullness, early satiety, diarrhoea and faecal incontinence, are 
disabling for the patient. The patient cannot eat all types of food and do 
not take part in any social life. The patients never know when 
hypoglycaemia could occur, thus further contributing to anxiety and 
depression. Impaired quality of life is also associated with GI symptoms 
(66). In our study in Paper IV, a decrease in severity of anxiety was only 
seen in the intervention group from baseline to the end of study. This 
result is in line with the results in earlier studies (162). However, the 
severity of depression did not was no change, neither within nor between 
the groups. Probably a longer study period than 20 weeks is needed, 
since the subjects need time to learn to change to SP diet and time to 
affect the depression. The quality of life assessed by SF-36 (mental and 
physical component) was not changed in any group. This may also 
depend on the short study period, as the effect on quality of life probably 
comes after the full effect of the dietary intervention. However, it also 
depends on other diabetic complications. The subjects in Paper IV had 
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several other severe diabetic complications, which has an impact on 
quality of life, as well as on psychological symptoms. To summarize, 
further studies with larger samples and longer study periods needs to 
evaluate the full dietary effect of SP diet on metabolic control, nutritional 
intake, body weight, psychological well-being and quality of life.   
The main cornerstone in our dietary treatment of insulin-treated DM 
gastroparesis was the particle size. In Paper III, it was shown that a diet 
with SP produces a more rapid gastric emptying rate. An indicator 
showing that the treatment works, is when the patient's hunger and 
appetite has returned (163). The MMC phase III in the stomach is of 
importance for gastric emptying of food with LP (164). Samsom et al 
confirmed in a small sample that MMC phase III was reduced in 
gastroparetic patients and in 50% of the subjects this motility phase did 
not occur at all (78). In a recent review it was concluded that the absence 
of MMC phase III has been associated with gastroparesis (151) and 
consequently it is important that the patient does not eat a diet with LP. To 
be successful with the treatment it is important to follow the intervention 
diet for every meal since a meal with LP could remain in the stomach for a 
long time depending on the degree of impairment of the patient's gastric 
emptying. It is also important to consider the motor function of the entire 
GI tract when giving dietary advice to patients with DM and gastroparesis, 
as many of these patients not only have upper GI symptoms, but also 
constipation, diarrhoea and faecal incontinence.   
Moreover, the carbohydrate content and the glycaemic index of the meal 
should be taken into account when giving dietary advice to patients with 
DM and gastroparesis. A solid meal with a high glycaemic index does not 
result in a high plasma glucose response because of delayed gastric 
emptying in the DM gastroparetic subject. However, if gastric emptying of 
a liquid meal or drinks are normal, the carbohydrates have shorter gastric 
emptying time than solid meals and therefore yields a high glucose 
response, which is negative, as hyperglycaemia further delays gastric 
emptying (53). This is important considerations when dietary advice is 
given to this patient group. 
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General conclusions 
1. A gastric emptying test with ROM is a widely available screening 
method to detect delayed gastric emptying in patients with diabetes, 
where a positive result seems reliable. However, a normal ROM test does 
not exclude delayed gastric emptying, and if the clinical suspicion of 
gastroparesis remains, scintigraphy should be performed.  
2. Patients with diabetic gastroparesis have a blunted postprandial plasma 
glucose response. Combining this information with the presence of GI 
symptoms can help clinicians identify diabetic patients with gastroparesis.   
3. A SP diet increases gastric emptying and the late postprandial 
glycaemic response in DM type 1 subjects with gastroparesis. 
4. Dietary treatment with a SP diet reduces the GI symptoms in insulin 
treated DM subjects with gastroparesis. 
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Summary in Swedish                                                                                                           
Gastropares (=långsam magsäckstömning) är en ofta förbisedd 
diabeteskomplikation. Prevalensen är osäker, men det har bedömts att 
30-40% av alla patienter med diabetes mellitus (DM) typ 1 har 
gastropares. Liknande prevalens har setts vid DM typ 2. Gastropares 
utgör för den enskilde patienten ett stort lidande, i form av bristande 
metabol kontroll, mag-tarm (GI) symtom och med näringsbrister som följd. 
Den tillförlitligaste undersökningen för att påvisa gastropares är scintigrafi, 
men tillgängligheten är dålig. Behandlingen av gastropares syftar till att 
förbättra metabola kontrollen, minska GI symtom och minska eller 
förebygga näringsbrister. Idag finns ingen randomiserad studie för hur 
kostbehandlingen vid gastropares ska vara utformad.                                                                                                                                                                              
Denna avhandling omfattar utvärdering av diagnosmetoder och 
kostbehandling vid gastropares.   
Arbete I. En alternativ utredningsmetod är att via röntgen följa röntgentäta 
markörers (ROM) tömning från magsäcken. Röntgen finns vid alla sjukhus 
Magsäckstömningen mätt med tömning av ROM med hjälp av röntgen 
jämfördes med magsäckstömningen av en isotopmärkt måltid via 
scintigrafi samma dag hos 115 patienter med DM Jämförelsen visade att 
om ROM testet visade långsam magsäckstömning, så var det 
gastropares, men om undersökningen visade normal tömning, så kunde 
gastropares inte uteslutas. Vid kvarstående misstanke om gastropares 
måste patienten utredas vidare. De GI symtom patienterna rapporterade 
var associerade med magsäckstömningen mätt med scintigrafi, men inte 
med ROM testet.  
Arbete II. En alternativ screeningmetod för gastropares studerades. 
Svårigheten av GI symtom kartlades under 2 veckor, därefter fick 
patienten äta en testmåltid. En ur diabetes synpunkt optimal måltid 
utgjorde testmåltiden. Plasmaglukos mättes vid ätstart av testmåltiden och 
sedan med jämna intervall under 3 timmar. Svårighetsgraden av GI 
symtomen korrelerade väl med patientens tidigare påvisade 
magsäckstömning, medan  blodsockersvaret efter testmåltiden var en 
något svagare prediktor för förekomsten av gastropares.   
Arbete III. Om matens partikelstorlek har ett samband med 
magsäckstömningen och blodsockersvaret studerades hos 
diabetespatienter med gastropares och en frisk kontrollgrupp. Samma 
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livsmedel och i samma mängder tillagades till två måltider med liten 
respektive stor partikelstorlek. Magsäckstömningen mättes med scintigrafi. 
Blodsocker togs inför undersökningen och under 3 timmar. 
Magsäckstömningen av måltid med stor partikelstorlek var mycket 
långsammare än måltiden med liten partikelstorlek hos bägge grupperna. 
Magsäckstömningen av måltiden med liten partikelstorlek tömdes lika fort 
hos patienterna som hos den friska kontrollgruppen. Blodsockerfallet var 
mindre och gick fortare över efter måltid i liten partikelstorlek i 
patientgruppen.   
Arbete IV. Vi randomiserade 56 patienter med insulinbehandlad DM och 
gastropares till kostbehandling med diabeteskost (kontrollgrupp) eller en 
försökskost med mat i liten partikelstorlek (försöksgrupp). Studien pågick 
under 20 veckor. Vid 7 besök instruerades patienterna om den kost som 
patienten blivit randomiserad till. Vid studiens inkludering och vid avslut av 
studien studerades: GI symtom, näringsintag och blodsockerinställning 
(HbA1c). I gruppen som åt kost med liten partikelstorlek hade GI 
symtomen förbättrats signifikant, vilket inte var fallet i kontrollgruppen. 
Fettintaget hade ökat marginellt, men statistiskt säkerhetsställt i 
försöksgruppen, men inte i kontrollgruppen. Metabola kontrollen hade inte 
ändrats i någon grupp.                                                                                                               
Denna avhandling vill förbättra utredningen, så att fler DM patienter med 
gastropers kan bli tidigare diagnostiserade genom att använda alternativa 
och mer tillgängliga diagnosmetoder som komplement till scintigrafi. 
Studierna visar också att aktiv kostbehandling med mat med liten 
partikelstorlek vid DM och gastropares minskar intensiteten av GI symtom 
och ger mindre blodsockersvängning efter måltid. 
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Future perspective   
Even though the studies in this thesis have expanded the knowledge 
about patients with DM and gastroparesis, they also reveal a need for 
more studies regarding treatment options and diagnostic methods for 
patients with DM and gastroparesis: 
Regarding diagnostic methods, a larger study assessing the clinical value 
of measuring gastric emptying with the ROM method in an unselected DM 
population would be useful.  
Moreover, a study measuring the correlation between gastric emptying 
assessed by scintigraphy and postprandial glucose response after a test 
meal at noon after a standard breakfast and a snack in the morning is 
another study that might yield clinically useful results.  
Also, further evaluation of the usefulness of GI symptom assessment in 
combination with assessment of the postprandial glucose response in 
defining gastroparetic patients in clinical practice in large, unselected 
patient groups is needed.  
Further investigations are also required to study the impact on the 
outcome of gastric emptying assessment depending on the composition of 
the most recent meals before the fasting measurement of gastric 
emptying. 
Our very promising treatment results in Paper IV need to be confirmed in 
randomised studies with larger number of subjects, but also with a longer 
study period, in order to see if the small particle diet in the long run may 
affect glycaemic control, metabolic factors and quality of life, and not only 
GI symptoms, as in our study.  
Furthermore, in order to spread the knowledge from this thesis regarding 
the importance of the particle size of the meal into clinical practice, it is 
imperative to train dieticians in dietary advice using SP meals and 
thereafter evaluate its usefulness in everyday clinical practice.  
Also, as patients with DM not only complain of upper GI symptoms, but 
also of constipation, diarrhoea, faecal incontinence and other lower GI 
symptoms, dietary advice that takes all GI symptoms into account needs 
to be developed and tested . 
The impact of treatment with an insulin pump in a randomised study with 
delayed bolus insulin infusion matching the gastric emptying rate is 
another clinical problem that needs to be studied. The same holds true for 
the use of the continuous glucose monitoring (CGM) technique in patients 
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with severe gastroparesis and recurrent, frequent hypoglycaemia and 
insulin coma despite dietary advice. 
To summarize, even though our studies have expanded the knowledge 
regarding DM and gastroparesis, substantial unmet needs for these 
patients are still present. 
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Appendix 1. INTERVENTION DIET  
Poorly digestible food   Medium digestible food  Easily digestible food  
Vegetables and Roots 
Raw: Carrots, Turnip, Parsnips  Cooked: Carrots, Turnip, Parsnips Mashed Turnips, Mixed Beetroot Pickled Beet 
Cooked Cauliflower and Broccoli Stem,  Cooked Cauliflower Flower, Broccoli Flower     
Asparagus Stalk      Asparagus Tip 
Green Pea       Green Pea Purée 
Boiled Corn       (Cooked and mixed) Corn paté 
Cooked Beans      (Cooked and mixed) Beans paté 
Cooked Brussels Sprouts      (Cooked and mixed) Brussels sprout paté 
Raw and Cooked Cabbage 
Raw, Boiled and Fried Mushrooms  Mixed Mushrooms  Mushroom Paste 
Boiled and Fried Onion      Fine Mixed Onion, Dried Powdered Onion  
Cooked Leeks      Mixed Leeks 
Rhubarb 
Salad, Cucumber, Tomatoes,      Canned Crushed Tomatoes, Tomato Paste 
Pepper    Pepper without Skin  Mixed Pepper 
Avocado       Mashed Avocado 
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Poorly digestible food   Medium digestible food  Easily digestible food 
Fruit and Berry 
Fresh Fruit    Cooked and Canned Fruit or Berry Puree of Fruit or Berry 
Skin and membrane of Citrus:  
Orange, Clementine, Grapefruit, Pineapple Ripe Pears without Skin  Ripe Pears without Skin, Canned Peach  
    Raspberries, Strawberries  Gooseberries 
Blueberries, Currant, and Lingo Berries     Mixed: Blueberries, Currant and Lingo Berries 
Blackberry, Cloudberries 
Green and Green-Yellow Banana  Yellow Banana  Yellow-Brown Banana 
Netted Melon   Kiwi, Soft Gala Melon  Mixed Kiwi, Water Melon 
    Mango, Papaya 
Nuts and Almonds      Flour of Nuts and Almonds 
Potato 
Fried Potatoes, French Potatoes  Boiled Potatoes, Baked Potatoes Mashed Potatoes, Pressed Potatoes, Creamed  
       Potatoes 
Pasta and Rice 
Pasta 
Parboiled Rice and Brown Rice,  
Non-Parboiled Rice Bulgur, Couscous Porridge 
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Poorly digestible food   Medium digestible food  Easily digestible food 
Bread 
White Fresh Bread   Wholegrain Cereal Flour Bread Brown crisp 
Bread with Seeds and Whole Grains  Bread Baked on Coarse Flour Bread Baked on Whole Meal Flour, Rye Crisp, Rusks 
Cheese 
Fat Cheese, Ripened Cheese  Cottage Cheese  Processed Cheese, Spreadable cheese, Quark 
  
Eggs 
Hard-Boiled Eggs, Soft Boiled Eggs     Mashed Boiled Eggs, French Omelet 
Pancakes 
Scrambled Eggs Made in Frying Pan  Scrambled Eggs Made in Pot Baked Omelet Swedish Style, Baked Egg 
Butter Pudding 
Meat 
Whole Meat    Minced Meat Dishes  Mixed Minced Dishes, Sausage 
    Jellied Veal  
    Extra-thin Slices of Ham 
Fish and Seafood 
Cured Salmon, Smoked Salmon  Baked Salmon  Baked Flatfish, Boiled Fish Loaf Dishes,  
       Fish Pudding 
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Poorly digestible food   Medium digestible food  Easily digestible food 
Raw Spiced Salmon   Baked Mackerel  Fish Soufflé, Fish Balls, Fish Pate, Fish gratin   
    Baked Cod Fish  Herring terrine,  
Shrimp, Crab, Clams, Tails     Mixed Shrimp, Crab, Clams, Tails 
 
Cooking Methods 
Raw, Wok     Cooked, Canned  Puree, Mixed, Pate, Timbale, Sauces 
Fried in a Pan, Deep-Fried, Wok  Roasted, Baked  Cooked  
Coating with Egg and Breadcrumbs, 
Coating with Breadcrumbs  
Fat Cooking Methods      Lean Cooking Methods 
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Appendix 2. CONTROL DIET  
Dietary treatment  
Beverages 
Free intake of beverages containing < 0.5 g carbohydrates/ 100 
ml ready to drink beverages 
Preparations to choose 
Raw or lightly cooked vegetables                                                                              
Fresh fruit and berries 
Foods providing good metabolic control: 
Bread made of whole grain and whole grain flour.                                         
Rice and pasta rather than potatoes  
Potatoes are allowed only in combination with raw or light cooked  
vegetables 
Pasta and rice with long cooking rather than with short cooking 
time 
Combination of food items to improve glycemic index                  
Legumes 
Food items to avoid 
Mashed potatoes and mashed turnips                                                               
Other mashed or mixed foods                                                              
Breads made of flour without grains and/or sourdough 
Fruit or berry compote or cream 
Canned vegetables 
Porridge, corn flakes and gruel 
Smooth soup   
Sweet drinks 
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Appendix 3 
PAGI-SYM 
(Swedish version) 
Detta frågeformulär handlar om hur svåra de symtom är som du eventuellt har i samband med 
dina mag-tarmproblem. Det finns inga riktiga eller felaktiga svar. Var snäll och svara på varje 
fråga så noggrant som möjligt. 
Vill du för varje symtom  ringa in den siffra som bäst beskriver hur  svårt symtomet var under de 
senaste 2 veckorna. Om du inte haft symtomet, ringa in siffran 0. Om symtomet var mycket milt, 
ringa in siffran 1. Om symtomet varit milt, ringa in siffran 2. Om det var måttligt, ringa in siffran 
3. Om det var svårt, ringa in siffran 4. Om det var mycket svårt, ringa in siffran 5. Se till att du 
besvarar alla frågor. 
 
Ange hur svåra följande symtom har varit under de senaste 2 veckorna. 
 
Ej Mycket  Mild    Måttlig    Svår  Mycket 
haft   mild   svår 
 
1. Illamående (kväljningskänslor som 0 1 2 3 4 5 
om du skulle kräkas) 
2. Ulkningar (kväljningar som om du 0 1 2 3 4 5 
skulle kräkas men inget kommer upp) 
3. Kräkningar 0 1 2 3 4 5 
4. Mättnadskänsla 0 1 2 3 4 5 
5. Oförmåga att äta upp ett normalt mål 0 1 2 3 4 5 
mat 
6. En känsla av att vara övermätt efter 0 1 2 3 4 5 
måltider 
7. Brist på aptit 0 1 2 3 4 5 
8. En känsla av uppkördhet (att du 0 1 2 3 4 5 
behövde lossa på dina kläder) 
9. Magen eller buken är synbart större 0 1 2 3 4 5 
10.    Smärta i övre delen av buken 0 1 2 3 4 5 
(ovanför naveln) 
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Ange hur svåra följande symtom har varit under de senaste 2 veckorna. 
 
 
Ej Mycket  Mild Måttlig  Svår  Mycke 
haft  mild     t svår 
 
11. Obehagskänsla i övre delen av 0 1 2 3 4 5 
buken (ovanför naveln) 
12. Smärta i nedre delen av buken 0 1 2 3 4 5 
(nedanför naveln) 
13. Obehagskänsla i nedre delen av 0 1 2 3 4 5 
buken (under naveln) 
14. Halsbränna (brännande smärta i 0 1 2 3 4 5 
bröstet eller halsen) under dagen 
15. Halsbränna (brännande känsla i 0 1 2 3 4 5 
bröstet eller halsen) när du ligger 
ner 
16. En känsla av obehag i bröstet 0 1 2 3 4 5 
under dagen 
17. En känsla av obehag i bröstet 0 1 2 3 4 5 
under natten (under sömnen) 
18. Uppstötningar eller reflux (vätska 0 1 2 3 4 5 
från magen som kommer upp i 
halsen) under dagen 
19. Uppstötningar eller reflux (vätska 0 1 2 3 4 5 
från magen som kommer upp i 
halsen) när du ligger ner 
20. Bitter, syrlig eller sur smak i 0 1 2 3 4 5 
munnen 
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Appendix 4 
Markera det alternativ som stämmer bäst för Dig.                                
Tänk inte för mycket, utan markera det alternativ som spontant känns 
rätt! 
 Jag känner mig spänd eller uppgiven:  
Ja, nästan hela tiden  
En stor del av tiden                                                                             
Av och till, tillfälligt    
Inte alls             
                                                                                                                                                        
 Jag finner nöje i saker som jag brukat ha glädje av: 
Ja, absolut 
Inte så mycket 
Bara lite 
Inte alls 
 
 Jag får en känsla som om något skrämmande är på väg att 
hända: 
Ja, absolut och att det är något 
förfärligt som ska hända 
Ja, men det som ska hända är 
inte lika hemskt  
Lite, men känslan skrämmer mig 
inte 
Har inte alls någon sådan känsla 
 
 Jag kan skratta och se det roliga i situationer: 
Så mycket som jag alltid gjort 
Inte lika mycket nu 
Inte alls så mycket nu 
Inte alls 
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 Skrämmande tankar kommer över mig: 
En stor del av tiden 
Ganska ofta 
Tillfälligt av och till  
Bara i undantagsfall 
 
 Jag känner mig glad: 
Inte alls 
Inte ofta 
Ibland 
Mest hela tiden 
 
 Jag kan sitta rofylld och känna avslappning: 
Alltid 
Vanligen 
Sällan 
Inte alls 
 
 Jag känns som om jag slagit ner på takten: 
Nästan hela tiden 
Mycket ofta 
Ibland 
Inte alls 
 
 Jag får en känsla av fjärilar i magen: 
Aldrig 
Tillfälligt 
Inte ofta 
Mycket ofta 
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 Jag har tappat intresset för mitt utseende: 
Ja, absolut 
Jag tänker sällan på mitt 
utseende 
Jag tänker ganska ofta på mitt 
utseende  
Jag tänker lika mycket på mitt 
utseende nu som jag gjort 
tidigare 
 
 Jag känner mig rastlös, som om jag skulle behöva gå iväg: 
Alltid 
Ganska ofta 
Inte ofta 
Inte alls  
 
 Jag ser på framtiden med tillförsikt  
Lika mycket som jag gjorde förr 
Mindre än vad jag gjorde tidigare 
Absolut mindre än vad jag brukat 
göra 
Inte alls 
 
 Jag får plötsliga panikkänslor: 
Ja, mycket ofta 
Ganska ofta 
Inte särskilt ofta 
Inte alls 
 
 Jag kan njuta av att läsa en bra bok, lyssna på radio eller se på 
TV 
Ofta 
Ibland 
Inte ofta 
Sällan 
Kontrollera att du svarat på alla frågor  
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Appendix 5 
 
 
 
 
 
HÄLSOENKÄT 
 
 
 
 
INSTRUKTION: Detta formulär innehåller frågor om hur Du ser på Din hälsa. 
Informationen skall hjälpa till att följa hur Du mår och fungerar i Ditt dagliga liv. 
 
Besvara frågorna genom att sätta en ring runt den siffra Du tycker stammer bast in på Dig.  Om Du ar 
osäker,ringa ändå in den siffra som känns riktigast. 
 
 
1.   lallmänhet, skulle Du vilja saga att Din hälsa ar: 
 
(Satt en ring runt en siffra) 
Utmärkt............................... .......................................................1 
Mycket god ....................................................................................2 
 
God ...................................................... ...........................................3 
 
Någorlunda..................................................................................4 
 
Dålig .................................................... .......................................S 
 
 
 
 
2.   Jämfört med för ett år sedan, hur skulle Du vilja bedöma Ditt allmänna hälsotillstånd nu? 
 
 
(Satt en ring runt en siffra) 
Mycket bättre nu an för ett år sedan.......................... ...................1 
Något bättre nu an för ett år sedan ...............................................2 
 
Ungefar detsamma............ ........................ .................................3 
 
Något sämre nu an för ett år sedan........ ...................................... 4 
 
Mycket sämre nu an för ett år sedan............................................5 
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 Ja, mycket 
begränsad 
Ja, lite 
begränsad 
Nej, inte 
alls 
begränsad 
a.   Ansträngande aktiviteter, som att springa, lyfta tunga 
saker, delta ianstrångande sporter 
1 2 3 
b.   Måttligt ansträngande aktiviteter, som att flytta ett bord, 
dammsuga, skogspromenader eller trädgårdsarbete 
1 2 3 
c.   Lyfta eller bära matkassar 1 2 3 
d.   Gå uppför flera trappor 1 2 3 
e.   Gå uppför en trappa 1 2 3 
f.   Böja Dig eller gå ner på knä 1 2 3 
g. Gå mer än två kilometer 1 2 3 
h.   Gå några hundra meter 1 2 3 
i.    Gå hundra meter 1 2 3 
j.   Bada eller klä på Dig 1 2 3 
 
 JA NEJ 
a.   Skurit ned den tid Du normalt ägnat åt arbete eller andra aktiviteter 1 2 
b.  Uträttat mindre än du skulle önskat 1 2 
C.    Varit hindrad att utföra vissa arbetsuppgifter eller andra aktiv eter 1 2 
d.  Haft svårigheter att utföra Ditt arbete eller andra aktiviteter (t.ex. 
aenom att det krävde extra anstränaninal 
1 2 
 
3.   De följande frågorna handlar om aktiviteter som Du kan tånkas utföra under en vanlig dag. Ar Du 
på grund av Ditt hälsotillstånd begränsad idessa aktiviteter nu?  Om så år fallet,hur mycket?   
                                                       
         (Sätt en ring runt en siffra på varje rad) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.   Under de senaste fyra veckorna, har Du haft något av följande problem i Ditt arbete eller med 
andra regelbundna dagliga aktiviteter som en följd av Ditt kroppsliga hälsotillstånd? 
 
         (Sätt en ring runt en siffra på varje rad) 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
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5. Under de senaste fyra veckorna. har Du haft något av följande problem iDitt arbete eller 
med andra regelbundna dagliga aktiviteter som en följd av känslomässiga problem (som 
t.ex. nedstämdhet eller ängslan)? 
                                                                            
                    (Sätt en ring runt en siffra på varje rad) 
   
 JA NEJ 
a.   Skurit ned den tid Du normalt ägnat åt arbete eller andra aktiviteter 1 2 
b.   Uträttat mindre anDu skulle önskat 1 2 
c.   Inte utfört arbete eller andra aktiviteter så noggrant som vanligt 1 2 
 
 
6.   Under de senaste fyra veckorna, ivilken utstrackning har Ditt kroppsliga halsatillstånd eller Dina 
känslomässiga problem stort Ditt vanliga umgänge med anhönga,vänner,gramar eller andra? 
 
(Sätt en ring runt en siffra) 
Inte alls .............................................. .........................................1 
Lite ..............................................................................................2 
 
Måttligt........................................................... ............................3 
 
Mycket  ................................................... ..... .............................4 
 
Väldigtmycket .............................................................................5 
 
 
 
7.    Hur mycket värk eller smärta har Du haft under de senaste fyra veckorna? 
 
(Sätt en ring runt en siffra) 
Ingen ..................................................................................... 1 
Mycket lätt  ................................................................................ 2 
Lått................................................. .............................. ........... ..3 
 
Måttlig .....................................................................................  .4 
 
Svår  ........................ .................................. ...................... 5 
 
Mycket svår ..................... ....................................................... ..6 
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Hela 
Tiden 
Största 
delen 
av 
tiden 
 
En hel 
delav 
tiden 
 
En del 
av 
tiden 
 
Lite 
av 
tiden 
 
Inget 
av 
tiden 
a.   Har Dukänt Dig riktigt pigg och stark? 1 2 3 4 5 6 
b.   Har Dukänt Dig mycket nervös? 1 2 3 4 5 6 
c.  Har Dukänt Dig så nedstämd att 
ingenting kunnat muntra upp Dig? 
1 2 3 4 5 6 
d.  Har Dukänt Dig lugn och harmonisk? 1 2 3 4 5 · 6 
e.  Har Du varit full av energi? 1 2 3 4 5 6 
f.    Har Du känt Dig dyster och ledsen? 1 2 3 4 5 6 
g.    Har Du känt Dig utsliten? 1 2 3 4 5 6 
h.   Har Du känt Dig glad och lycklig? 1 2 3 4 5 6 
i.     Har Du känt Dig trött? 1 2 3 4 5 6 
 
8.  Under de senaste fyra veckorna. hur mycket har varken eller smärtan stört Ditt normala arbete 
(innefattar både arbete utanför hemmet och hushållssysslor)? 
 
(Sätt en ring runt en siffra) 
Inte alls ........ .............................................. ........................... ..1 
Lite ........ ...................................... .................. ..... . .............. . 2 
 
Måttligt........ ..................................................... ..... . ........... .  ..3 
 
Mycket  ............ ...........................................................................4 
 
Väldigt mycket  ...................... ..... ......... ................... ..............5 
 
 
 
9.    Frågorna här handlar om hur Dukänner Dig och hur Du haft det under de senaste fyra ve  ckorna. 
Ange för varje fråga det svarsalternativ som bast beskriver hur Dukänt Dig. 
Hur stor delav tidenunder de senaste fyra veckorna.  
(Sätt en ring runt en siffra på varje rad) 
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Stämmer 
precis 
 
stämmer 
ganska bra 
 
 
Osäker 
Stämmer 
Inte 
särskilt bra 
 
Stämmer 
inte alls 
a.   Jag verkar ha lite 
lättare att blisjuk än 
andra människor 
1 2 3 4 5 
b.   Jag ar lika frisk som 
vem som helst av 
dem Jag känner 
1 2 3 4 5 
c.  Jag tror min hälsa 
kommer att bli 
sämre 
1 2 3 4 5 
d.   Min halsa ar utmärkt 1 2 3 4 5 
 
1O. Under de senaste fyra veckorna,hur stor del av tiden har Ditt kroppsliga hälsotillstånd eller Dina 
känslomässiga problem stört Dina möjligheter att umgås (t ex hälsa på släkt, vänner, etc.)? 
 
(Sätt en ring runt en siffra) 
Hela tiden ....... ........................................ ......  ...........1 
Slörsta delen av tiden ...................................................................2 
 
En delav tiden....... ............................... .... .................................3 
 
Lite av tiden ............................ ............. .....................................4 
 
Inget av liden..............................................................................5 
 
 
 
11. Välj det svarsalternativ som bäst beskriver hur mycket vart och ett av följande påståenden 
STÅMMER eller INTE STÅMMER in på Dig. 
                (Sätt en ring runt en siffra på varje rad) 
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